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ABBREVIATIONS
D - deletion
m - micro
6-well - one well of 6-well plate
Amp – ampicillin
BAC - bacterial artificial chromosome
BCR – B-cell receptor
ca. - circa
CAM – chloramphenicol
CD – cluster of diifferentiation
chlorores/ampsen - chloramphenicol resistant and ampicillin sensitive
CsCl – cesium chloride-ethidium bromide centrifugation density gradient
DNA – deoxyribonucleic acid
dNTP – deoxyribonucleotide (dATP, dCTP, dGTP, dTTP)
E.coli – Escherichia coli
e.g. – for example
EBNA – EBV nuclear antigen
EBV – Epstein-Barr Virus
ECACC - European Collection of Animal Cell Cultures
EtBr – Ethidium Bromide
F - farad
FACS – flow cytometry
FBS – fetal bovine serum
FCS – fetal calf serum
G418 – antibiotic, resistance to it is encoded in neomycin gene
GC – germinal centre
GFP – green fluorescent protein
h(s) – hour(s)
HAT – selection medium containing Hypoxanthine/Aminopterin/Thymidine
HHV – Human Herpes Virus
HIV – Human Immunodeficiency Virus
HLA – human leukocyte antigen
Hprt – hypoxanthine phosphoribosyltransferase
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hyg - hygromycin
IM – infectious mononucleosis
InvTarg – my final recombinant maxi-EBV targeting vector
Kac – potassium acetate
kb – kilo base pairs
KSHV – Kaposi’s Sarcoma Herpesvirus
l - liter
L2000 – lipofectamine 2000
LB – Luria Broth
LCL – lymphoblastoid cell line
LCV - lymphocryptovirus
LIF – leukemia inhibitory factor
LMP – latent membrane protein
m - milli
M - molar
mES cells - murine embryonic stem cells
MHV-68 – murine herpesvirus 68
min. - minute
n - nano
NaAc – sodium acetate
NaAc – sodium acetate
neo – neomycin (G418) selection medium
No - number
nt - nucleotide
o/n – overnight
OD – optical density
OPTI – Opti-MEM transfection medium
OriLyt – lytic origin of viral DNA replication
OriP – origin of DNA replication
p - piko
PBS – phosphate-buffered saline
PCR – polymerase chain reaction
PFGE – pulse field gel electrophoresis
PGK – phosphoglycerol kinase
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RNA – ribonucleic acid
Rnase - ribonuclease
rpm – rotations per minute
RT – room temperature
sec. – second(s)
SSR – site-specific recombinase
SV40 – simian virus 40
tet - tetracycline
TR – terminal repeats
U – unit(s)
UV - ultraviolet
V – volt
w/v – weight per volume
WHO – World Health Organisation
wt – wild-type
zeo - zeocin
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1. INTRODUCTION
1.1. Epstein-Barr Virus (EBV) – an unusual human virus
Epstein-Barr Virus (EBV), known also as Human Herpes Virus 4 (HHV4), belongs to
the large family of herpesviruses and is categorized as a g1-herpesvirus or
Lymphocryptovirus subfamily (Tselis et al., 2004). Herpesviruses share common
features of their structure and biology. They are enveloped viruses with large
genomes of double-stranded DNA. Generally, these viruses can cause various
diseases in humans and animals. ‘Herpein’ from Greek denotes ‘to creep’, what
refers to the ‘sneaky’ nature of the viruses and reflects their ability to remain silenced
in the infected host and to re-appear. Several viruses belong to the three different
subfamilies of Human Herpesviruses (HHV): Herpes Simplex Virus 1 and 2 (HSV-1
or HHV1, HVS-2 or HHV2) and Varicella-Zoster Virus (VZV or HHV3) form the
subfamily of a-herpesviruses, Cytomegalovirus (hCMV or HHV5), Human
Herpesviruses 6 and 7 (HHV6, HHV7) belong to b-herpesviruses, and Kaposi’s
Sarcoma Herpesvirus (KSHV or HHV8) are members of the g-herpesviruses
(McCance, 1998). A vast number of animal herpesviruses has been discovered.
Murine g-herpesvirus MHV-68 and different primates’ lymphocryptoviruses deserve
special attention in the context of EBV, because these related viruses show common
characteristics.
EBV is an extremely successful virus with a peculiar life style. Although more than
95% of the human population is infected with EBV (WHO, 2006), very few individuals
develop EBV-related diseases. They include Infectious Mononucleosis (IM), which
can result from a primary infection with EBV as well as several EBV-associated
tumours. The range of the disorders EBV provokes is considerably wide and the
expression pattern of the viral genes differs from one disease to the next (Kuppers,
2003). It seems conclusive that a particular expression pattern of viral genes is the
molecular link between their functions and the phenotype of the infected cell.
Epstein-Barr Virus (EBV) is a tumour herpesvirus with a very narrow host range
infecting strictly humans (McCance, 1998). It infects preferentially human B cells, but
it is also often detected in epithelial cells (Young and Rickinson, 2004) and
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sporadically in other cells of the hematopoietic system, including T lymphocytes,
monocytes, granulocytes and Natural Killer (NK) cells (Knecht et al., 2001).
EBV is a large enveloped herpersvirus with linear double-stranded DNA packaged in
a protein capsid (Fig.1.1).
Glycoprotein spikes are inserted into the outer layer of the
envelope (Klein, 1998). The linear virion genome
circulates upon infection and persists in the nucleus of the
host cell during its proliferation and resting state. Upon
virus synthesis, the viral genome becomes linearized and
is packaged into the virus capsid (Kuppers, 2003). In
latently infected cells EBV DNA is mostly found in a
multiepisomal form, only sporadically integrating into the
host genome (Knecht et al., 1997; Miller, 1990).
Fig.1.1. Structure of the EBV herpesvirus. (modified from Klein,
1998) Envelope consists of a lipid bilayer with glycoprotein spikes.
Protein tegument surrounds the nucleocapsid with 162 capsomeres
and the double-stranded genomic DNA.
Two viral envelope glycoproteins are known to assist virus entrance into the host cell:
gp350 and gp42. gp350 binds to the human CD21 receptor on the B cell surface, and
the cell surface protein Human Leukocyte Antigen class II (HLAII) acts as a co-
receptor for the viral glycoprotein gp42. The exact steps how EBV enters other cell
types have not yet been well defined (Young and Rickinson, 2004). It seems that
there are alternative ways since e.g., epithelial cells do not express CD21 receptor
(Janz et al., 2000). After binding of the virus, it is endocytosed. Upon a fusion
between the viral and cellular membranes the viral tegument and the nucleocapsid
are released into the cytoplasm. The capsid is then transported to the nuclear pores
via the cellular cytoskeleton and the EBV DNA is released into the nucleus
(McCance, 1998).
As already mentioned EBV is an unusual virus. As such, its control over the host cell
is not limited to virus production (Kuppers, 2003). EBV additionally exploits the host
organism in its latent phase multiplying its genome further in the course of the virus-
driven host cell proliferation. Thereby it is able to persist in its dormant state for the
host’s lifetime in resting B cells. In this silenced state EBV expresses a minimal set of
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genes (Young and Rickinson, 2004). The resting form of the virus will be named a
‘silenced state’ in this work, and the term ‘latent’ will refer to the EBV ‘latent cycle’.
1.2. Gene expression of EBV
The EBV genome of about 184kb double-stranded DNA encodes nearly 100 genes.
Around 90 of them are expressed during the lytic replication and are classified in
three groups of immediate early, early and late proteins. Generally, the immediate
early genes play a role in regulating gene expression of the virus, the early genes
encode enzymes which are important for EBV DNA replication, and the late genes
encode structural proteins of the virion. Some of those genes are also expected to
participate in the viral immune evasion (Tselis et al., 2006). During its latent cycle
EBV expresses only eleven genes, nine of which encode viral latent proteins: six
EBV nuclear antigens (EBNAs): -LP, -1, -2, -3a, -3b, -3c, and three latent membrane
proteins (LMPs):  -1, -2a, -2b. The latent proteins are engaged in supporting B cell
transformation in vitro by altering cellular signalling pathways or/and transcription
(Young and Rickinson, 2004). Although the in vivo functions of the latent gene
products are not clearly defined, the state of current knowledge is summarized in
Tab.1.1. The viral proteins sustain the hidden state of viral infection, but can also
determine activation and proliferation of the host cell (Young and Rickinson, 2004).
Several of the latent gene products have been shown to retain similar functions as
their cellular counterparts summarized in Tab.1.1. Although all latent genes are
expressed in virus-induced proliferation of B cells during latency III, only EBNA2,
EBNA3a and c, LMP1 and EBNA-LP are crucial for B cell outgrowth in vitro, along
with EBNA1 for episomal genome maintenance. LMP2a and b (Young and
Rickinson, 2004) and EBNA3b (Murray and Young, 2001) are dispensable.
Transgenic mice with latent viral genes expressed from heterologous
(immunoglobulin heavy chain or SV40) promoters were established. Transgenic mice
with overexpressed LMP1 or EBNA2 develop tumours (Kulwichit et al., 1998,
respectively; Tornell et al., 1996). EBNA1’s ability to induce tumourogenesis in
transgenic mouse is controversial. First, EBNA1 had been found to stimulate B cell
neoplasia (Wilson et al., 1996), but this finding could not be confirmed (Kang et al.,
2005). LMP2a is not oncogenic but can bypass B cell development (Portis and
Longnecker, 2004).
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Name Function Mimicking
cellular
genes
Transformation
potential in vitro
Tumour
formation
potential in vivo
EBNA1 -  ma in tenance  and
replication of episomal EBV
- transcriptional regulation
of EBNAs and LMP1
High mobility
group protein
A1 (HMGA1a);
(Thomae A., in
preparation)
-
(except of genome
maintenance)
+/-*
(o/ex)
EBNA2
(TF)
- transactivation of viral
genes (LMP1, LMP2a) and
certain cellular genes
Notch
(binding to RBP-
Jk)
+
(E)
+
(o/ex)
EBNA-LP - co-operation with EBNA2
in transactivation
+*
(EG)
EBNA3a +
(E)
EBNA3b -
EBNA3c
- repression of EBNA2-
mediated transactivation
+
(E)
LMP1 - promotion of B cell
activation and proliferation
CD40
(act ivat ion of
NFkB pathway)
+
(E)
+
LMP2a - role in B cell proliferation
and survival in absence of
BCR
- role in immune evasion
B-cell receptor
(BCR)
+
(NE)
-
(influences B cell
development)
LMP2b - possible regulation of
LMP2a function
-
Tab.1.1. Latent gene products of EBV. (adapted from Kuppers, 2003; Murray and Young, 2001;
Young and Rickinson, 2004) (*): not consistent, controversial data; EBNA: EBV Nuclear Antigen, LMP:
Latent Membrane Protein, TF: transcription factor, o/ex: overexpression from a heterologous
promoter, BCR: B cell receptor, E: essential, NE: not essential, EG: required for efficient proliferation.
Diverse expression patterns of the latent EBV proteins were identified. Because
conflicting views exist on the classification of the EBV latency programs, I present
one version, only. This characterization includes five programs of EBV latent gene
expression (Tab.1.2). The occurrence of those individual patterns is linked to the host
cell tropism, stage of the cellular development (Fig.1.4a), or kind of EBV-positive
tumour (Tab.1.3).
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Latency program Latent proteins expressed
0 (EBV latency state) EBNA1, LMP2a
I EBNA1
II EBNA1, LMP1, LMP2a
I/II EBNA1, LMP2a and b, LMP1*
III (EBV replicating state) EBNA1, EBNA2, EBNA3a, b and c, EBNA-LP,
LMP1, LMP2a and b
Tab.1.2. EBV latent proteins expression patterns. (based on Kuppers, 2003; Young and Rickinson,
2004)); (*): not always occurs; EBNA: EBV Nuclear Antigen, LMP: Latent Membrane Protein.
Beside the nine latent genes a number of non-coding viral RNA was also detected in
all the latency programs. The transcripts comprise: BamHIA rightward transcript
(BART), encoded by the BamHIA region, non-coding EBV-encoded RNAs (EBERs),
EBER1 and EBER2 (Young and Rickinson, 2004), and several microRNAs (Pfeffer et
al., 2004). The role of the non-coding transcripts is still under debate. Several
potential open reading frames can be detected in the multiply spliced family of BART
transcripts. One of them has been shown to have oncogenic properties in vitro, but
their expression is questionable in EBV-infected cells. EBERs, which are expressed
at more than 105 molecules per latently infected cell, are not essential for the
transformation of human primary B cells (Young and Rickinson, 2004). They seem to
negatively regulate antiviral effects of the host cytokine network (Nanbo et al., 2002).
1.3. B cells and their development
B cells are the main targets of an EBV infection in vitro and in vivo (Young and
Rickinson, 2004). B cells, or B lymphocytes, are components of the immune system.
They guard the peripheral tissues while circulating in the blood and in a specialized
system of vessels, the lymphatic system. B cells, in cooperation with T lymphocytes,
are able to mount specific immune responses against the wide range of pathogens
encountered during lifetime. This is enabled by a high diversity of cell surface
receptors, B-cell receptors (BCR) for B cells, which are unique for each mature
lymphocyte. Upon activation B cells differentiate into plasma cells and release
antibodies. All the cellular components of blood, red and white blood cells and
platelets, develop from hematopoietic stem cells (HSC) in the bone marrow (BM). B
and T lymphocytes originate from a common lymphoid progenitor, a stem cell of
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more limited potential. The same progenitor gives rise to a third lineage of natural
killer (NK) cells, which however, lack the antigen specificity, and as a part of the
innate immunity can remove abnormal cells from the organism. Only B cells originate
and mature in BM, T cells complete their maturation in thymus. Once the
lymphocytes complete their maturation they enter the blood stream and migrate to
the peripheral lymphoid tissues, such as spleen and lymph nodes, gut-associated
lymphoid tissue (GALT), including tonsils and adenoids, bronchial-associated
lymphoid tissue (BALT) and mucosal-associated lymphoid tissue (MALT). The
circulating mature or naïve B cells are prepared to encounter and to be activated by
the appropriate antigen (Janeway et al., 2005). Upon such activation B cells create a
so-called germinal centres (GC) in the primary follicle of the secondary lymphoid
organ (Fig.1.2). After the activated B cells enter the GC, they undergo rapid
proliferation and differentiation. The extensively proliferating B cells in GC, called
‘centroblasts’, acquire somatic mutations in a process of ‘somatic hypermutation’ in
order to increase the affinity of their BCR to the encountered antigen. The
centroblasts then differentiate into resting centrocytes, which are verified in their
ability to interact with the antigen presenting cells, such as helper T cells and
dendritic cells, and thus, to recognize the antigen. B cells which survive this selection
differentiate further into memory B cells or plasma cells and leave the GC.
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Fig.1.2. Antigen-activated B-cell development in the germinal centre. (modified from Kuppers,
2003 and Janeway et al., 2005) Mature B cells upon stimulation by antigen (interaction with Th and
DC) migrate to the primary lymphoid follicles of the secondary lymphoid organs, such as lymph nodes.
There, they reach the highly proliferative state of centroblasts, which form a germinal centre. In the
outcome of somatic hypermutation (SHM) many antibody variants are generated. The resting
centrocytes, which acquired higher affinity to the antigen upon SHM survive the selection process on
the basis of an interaction with the Th and DC. The other GC B cells with disadvantageous mutations
undergo apoptosis. The immunoglobulin genes of the positively selected centrocytes are then
remodelled by class switching, which replaces the originally expressed immunoglobulin heavy-chain
constant region genes by these of another class. Finally, the centrocytes, which are approved by the
antigen verification, differentiate either into antibody-producing plasma cells or quiescent, resting
memory B cells. Th: T helper cell, DC: dendritic cell, GC: germinal centre, FDC: follicular dendritic cell,
SHM: somatic hypermutation.
primary 
lymphoid follicle
artery
vein
secondary
lymphoid follicle
afferent
lymphatic vessel
efferent 
lymphatic vessel
paracortical area
(mostly T cells)
germinal centre
Lymph node
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1.4. Biology of EBV infection in vivo
The data on in vivo EBV infection stem from healthy carriers and patients with EBV-
related diseases. EBV is orally transmitted and the infectious virus can be detected in
oral secretions from Infectious Mononucleosis (IM) and immunosupressed patients,
and at lower levels also from the virus carriers. Two different states of the virus - a
lytic and a latent state - were distinguished in the experiments involving a viral
replication inhibitor (acyclovir). Acyclovir eliminates virus excretion from the
oropharynx (behind the oral cavity) but does not affect the level of latent infection in B
cells. Moreover, only mature B cells can host the latent virus as the patients with X-
linked agammaglobulinaemia (XLA) are not able to establish latent EBV infections
(Murray and Young, 2001). Studies on the viral primary infection were performed with
IM patients, and the following conclusions were made. EBV is shed from epithelial
cells and B cells located in the oropharyngeal sites. The virus induces proliferation of
infected naïve B cells in lymphoid tissues, and by expressing a full set of the viral
latent genes it provokes specific cytotoxic T cell responses against EBV proteins
(Young and Rickinson, 2004). Silenced EBV, non-replicating and expressing a limited
gene set, persists in memory B cells of peripheral blood of IM patients (Murray and
Young, 2001). Observations made with healthy virus carriers shed more light on
persistent infections with EBV. Those people host also a silenced form of the virus in
their memory B cells of the peripheral blood (Kuppers, 2003).
Several models of the EBV infection in vivo exist. Here, I refer to the infection model
proposed by Young et al. (Fig.1.3).
After primary infection when EBV enters the human oropharynx where the lytic
replication occurs, it infects B cells in the local area (Fig.1.3a). A full set of the viral
latent proteins (latency III) is expressed in EBV-transformed B cells, whose outgrowth
is controlled by the EBV-specific T cells. The virus becomes silenced (latency 0) and
persist hidden in resting B cells for the host life-time. Most of the researchers agree
that EBV in its silenced state persists in memory B cells, though, it is a matter of
debate how the virus reaches this B cell compartment. In the presented model both
ways of EBV entry into memory B cells are considered: direct infection of memory B
cells, as well as an infection of naïve B cells and their passage through a germinal
centre (GC).
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Fig.1.3. Model of EBV infection in a healthy individual. (modified from Young and Rickinson, 2004)
(a) In the primary infection orally transmitted EBV enters the organism in the area of oropharynx and
undergoes a lytic cycle in the local epithelium. EBV infects both naïve and memory B cells and
stimulates their proliferation, which is negatively controlled by cytotoxic T cells abrogating uncontrolled
B cell expansion. The proliferating B cells express the full latent EBV program (latency III). Naïve cells
develop to memory cells in germinal centres, where the expression of EBV latent proteins is restricted
to program I and II, and the virus ends up finally in the silenced state (latency 0) hiding in the memory
B reservoir. The memory B cells infected directly in the proximity to epithelium do not need to traverse
the germinal centre. Upon clonal expansion with expression of the full set of EBV latent genes (latency
III) EBV in those cells becomes also silenced (latency 0). (b) The reactivation of the virus in the course
of a persistent infection is initiated in the silenced memory B cells. They become recruited to the
germinal centre, and they either reconstitute the memory B cell reservoir or differentiate to plasma
cells. The latter give rise to virus progeny, which is then released through epithelium (oral
transmission), or/and infects new B cell targets within the lymphoid tissue. CTL: cytotoxic T
lymphocytes; EBV latency programs: I - EBNA1, II - EBNA1, LMP1, LMP2a, III - all latent genes.
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The main argument in favour of the first scenario is the observation that EBV has an
ability to infect not only naïve but also memory and GC B cells of IM patients.
Additionally, it was reported that EBV-infected B cells of IM patients show no ongoing
hypermutations within the expanding clones, and they were absent in the GC areas
(Kurth et al., 2000). On the other hand, this scenario does not explain the
disappearance of the infected naïve B cell population. The second theory is based on
the similarities between EBV activation of B cells upon infection and the process of B
cell antigen stimulation (Thorley-Lawson, 2001). These similarities are apparent and
suggestive because different viral latent gene products mimic the basic antigen
stimulation signals crucial for B cell survival and differentiation in the course of the
germinal centre reaction (Fig.1.4). Upon activation by antigen the proliferating naïve
B cells form germinal centres (GC), where the secondary contact with the antigen
positively selects B cells with improved affinity. EBV seems to mimic the B cell
activation process with its latent proteins (latency III program) and allow positive
selection of B cells expressing a limited set of the viral proteins (latency II program)
(Fig.1.4a). Naïve B cells become activated and later approved by binding of antigens
to their B-cell receptors (BCR) and via interaction with activated helper T cells (Th)
through the CD40 receptor on B cells (Fig.1.4b). EBV imitates the BCR- and CD40-
derived signals with its latent proteins, LMP2A and LMP1, respectively (Thorley-
Lawson, 2001).
During persistent EBV infection the virus-hosting memory B cells occasionally may
become recruited to the GC and they either re-enter the memory B cell reservoir or
differentiate into plasma cells to give rise to progeny virus (Fig.1.3b). The viral
particles can be shed from the mucosal epithelium or infect new naïve and memory B
cells.
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Fig.1.4. Similarities between B cell differentiation and EBV infection. (adapted from Thorley-
Lawson, 2001; Thorley-Lawson and Babcock, 1999) (a) This model proposes an infection of naive B
cells as a necessary step on the viral route to memory B cells. Mature, naive B cells undergo blast
transformation both upon primary antigen stimulation and EBV infection. Those proliferating B cells
establish a germinal centre as proliferating centroblasts, which differentiate further to centrocytes with
improved affinity to the antigen. EBV latent expression is then limited to latency I and II programs. The
secondary contact of the differentiating B cells with antigen and T helper cells decide about B cell
survival by a verification of the affinity of their mutated B-cell receptors to the cognate antigen. Most
likely EBV imitates signals from the BCR and CD40 surface proteins with its latent genes, LMP2a and
LMP1, respectively. (b) B cells become stimulated by antigen via their B-cell receptor (BCR), and the
interaction with activated T helper cells, which engage CD40 receptor on the B cell surface. GC:
germinal centre, SHM: somatic hypermutation, Ag: antigen, BCR: B cell receptor; EBV latency
programs: 0 - LMP2a, I - EBNA1, II - EBNA1, LMP1, LMP2a, III - all latent EBV genes expressed.
1.5. EBV-associated human diseases
Upon EBV infection the human host remains a carrier for a lifetime. If the first contact
with the virus occurs early in childhood, the infection course is predominantly
asymptomatic (Kuppers, 2003). Delayed contact with EBV leads in 30% of the cases
to Infectious Mononucleosis (IM), so-called ‘kissing disease’, after oral transmission
of the virus (WHO, 2006). Massive proliferation of B cells in IM is usually limited by
the host immune system within few weeks (Kuppers, 2003). In some cases EBV
leads to tumour development (malignancies associated with EBV infection are
summarized in Tab.1.3).
naive B
B blast
centroblast
centrocyte
memory B
Normal B-cell
differentiation
EBV
infection
Latency III
ACTIVATION
Latency I
Latency 0
Latency II
Ag and T cell 
stimulation:
BCR
CD40
Ag and T cell 
stimulation:
BCR
CD40
BCR
GC
SURVIVAL
B cell
BCR
Ag
T helper cell
CD40R
CD40
ligand
a) b)
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Malignancy EBV association
(%)
EBV
latency
Cellular origin
of malignant
cells
Associated
factors
Deregulation
at molecular
level
Burkitt
Lymphoma (BL)
95-100 (endemic)
20-30 (sporadic)
I centroblasts
(GC)
malaria, phorbol
e s t e r s  f r o m
plants,
temperature and
humidity
translocation,
LOH,
myc, p53, Rb
involvement
Hodgkin Disease
(HD)
40 (Western world)
9 0  ( c e n t r a l
America, children)
II pre-apoptotic
(‘crippled’) GC B
cells
NFkB
activation
Posttransplant
lymphoprolife-
rative disease
(PTLD)
80 III
(also I
or II)
usually GC B
cells (sometimes
crippled)
immune
suppression**
AIDS-associated
Lymphomas*
30-100 I or III GC or post-GC B
cells
immune
suppression**,
chronic antigenic
stimulation
Undifferentiated
Nasopharyngeal
Carcinoma
(uNPC)
100 I/II epithelial cells fumes, smoke,
s a l t e d  f i s h ,
chemicals
Gastric
carcinoma
10 I/II epithelial cells
T lymphoma
EBV(+)
5-50 I/II h e l p e r  a n d
cytotoxic T cells
Extranodal
lymphoma
5-50 I/II mostly NK cells
Tab.1.3. EBV-associated diseases. (adapted from Kuppers, 2003), (supplemented with data from
Young and Rickinson, 2004, Murray, 2001 #93, WHO ) BL - Burkitt Lymphoma, GC- germinal centre;
LOH- loss of heterozygosity; NK-Natural killer cells; (*): including PCNSL - Primary Central Nervous
System Lymphomas, BL, PEL - Primary Effusion Lymphomas, DLCL - Diffuse Large-Cell Lymphoma
(CB- centroblastic or IB- immunoblastic); (**): in the course of transplantation, radio- or chemotherapy.
EBV is linked mainly to lymphomas but it is also associated with epithelial cancers
(Wensing and Farrell, 2000). EBV occurrence in tumour cells varies between the
diseases. The virus is found with high frequency in B cell lymphomas (particularly in
certain world regions), rather rarely in epithelial cancers and variably in T- and
Natural Killer (NK)-cell lymphomas (Tab.1.3). The malignant cells infected with EBV
exhibit distinct viral expression patterns in those various disorders, what might be
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connected with their cellular origin. Several of the EBV-related tumours are meant to
be associated with the environmental or/and genetic factors (Young and Rickinson,
2004). EBV-related diseases are encountered worldwide, however, some tumour
types are more common in certain areas. For instance, ‘endemic’ Burkitt Lymphoma
(BL) occurs mainly in New Guinea and Africa, with an incidence of 6-7 cases /100
000 in year (WHO, 2006). While the ‘sporadic’ BL is seen in the developed world with
approximate 50-fold lower incidence (Murray and Young, 2001). Nasopharyngeal
Carcinoma (NPC) is especially common in South-East Asia (1-10cases/100 000 in
year) (WHO, 2006). T- and NK-cell lymphomas occur also most often in South-East
Asia, and although the progenitor cells are rarely infected with EBV, they carry a high
risk of lymphoma development. There is an incidence of 75 000 of new EBV-positive
gastric carcinoma patients annually (Young and Rickinson, 2004). Hodgkin disease
(HD) shows no geographical preference and is rather rare (1-3 cases /100 000 in
year) (Murray and Young, 2001).
It has been observed that EBV-associated tumours, which are not directly linked to
immune suppression involve additional environmental or genetic factors for their
development (Young and Rickinson, 2004).
1.6. Transgenic murine model systems
Transgenesis has become a very common approach to study genes functions and to
establish animal models for human diseases. The mouse is a favourite small animal
used worldwide in this field. Its short reproduction period, high homology of its
genome to human sequences and an optimal size for organ and tissue investigations
are the main advantages of this in vivo model system (Williams and Wagner, 2000).
Two most common methods in mouse transgenic research comprise microinjection
of the transgene DNA into a fertilized murine egg and development of a transgenic
mouse from a genetically targeted embryonic stem (ES) cell clone (Fig.1.5). The
latter method enables a specific integration of a transgene into the murine genome
however, it is more work- and time-consuming (Williams and Wagner, 2000).
1.6.1. Microinjection of the transgene for random integration
The microinjection technique is based on the injection of the transgene directly into a
fertilized mouse egg, where it integrates randomly into the mouse chromosome
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(Fig.1.5A). The insertion takes place most often at one site, but it can also happen at
two or more sites on different chromosomes (Vintersten et al., 2004). About 70% of
the eggs survive this procedure (data from cooperating group of E.Wolf, Gene
Centre, Munich) and can be transferred directly to a foster mother. As an outcome of
this procedure the offspring is genetically homogenous straight away, unless
recombination of the foreign DNA takes place after the first cell divisions. In that
case, the offspring will be mosaic for the transgene (Williams and Wagner, 2000).
Fig.1.5. Random (A) and site-specific (B) transgene insertion into the murine genome. (Williams
and Wagner, 2000) (A) Random integration takes place upon microinjection of a transgene construct
into the male pronucleus of a fertilized mouse egg. The early embryo is transferred into a
pseudopregnant foster mother, which gives birth to a transgenic mouse. (B) Targeting construct
equipped with homologous flanks for the integration in the genome is transfected into embryonic stem
(ES) cells, which are subsequently selected in vitro for the presence of the transgene. The desired ES
cell clone with correctly integrated transgene is injected in the mouse blastocyte, which is then
transferred into a foster mother. The chimeric offspring, which transmits the transgene in the germ
line, gives rise to a heterozygous transgenic mouse upon cross-breeding. Further cross-breeding of
the heterozygous mouse leads to a mouse homozygous for the inserted transgene.
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During random transgene insertion the gene of interest is embedded in heterologous
transcription regulatory sequences to direct its expression to a chosen cell type. This
method is preferably applied when a recombinant protein is expressed to alter an
animal biology and when studying transcriptional control (Williams and Wagner,
2000). Although random transgenesis is a very straightforward method, it also has
some negative sides. Transgenes are often expressed under control of strong
promoters, which may influence the expression of neighbouring genes. The
transgene integration as such can interrupt expression of the genetic locus since the
transgene can act as an insertional mutagene. Moreover, complete accidental
inactivation of a gene necessary for embryonic development prevents further studies
of such a ‘knock-out’ offspring. Lastly, uncontrolled expression of a given transgene
in many different tissues may eventually lead to inexplicable results (Tronche et al.,
2002).
1.6.2. Embryonic stem (ES) cell targeting
The pluripotent potential of the embryonic stem (ES) cells was discovered in the early
eighties. ES cell lines, which maintain an undifferentiated state in vitro, were
established upon ES isolation from murine and human embryos. After the
implantation of the cultured ES cells back into an early blastocyste embryo they
contributed to all cell types, including germ line in the resulting mouse chimera
(reviewed in Wobus and Boheler, 2005). In parallel, it was observed that DNA
fragment newly introduced into a mammalian cell can integrate into the genome via
homologous flanks. This process is called homologous recombination (Folger et al.,
1982). A combination of these two significant discoveries resulted in the creation of a
transgenic mouse from ES cells targeted at a particular predetermined site through
homologous recombination. Since then this approach is widely applied in transgenic
research (Thomas and Capecchi, 1987).
ES cells targeting takes place at their undifferentiated state by transfection of a
transgene, which integrates specifically into the ES cell genome (Fig.1.5B) via a
homologous recombination event, or as a result of site-specific recombinase (SSR)
action (Wobus and Boheler, 2005). Most often the transgene carries positive or
negative selection markers what easies further analysis of the transfectants
(Bockamp et al., 2002). ES cell clones with the desired genetic modification are then
chosen on the basis of a genetic screen. Southern blotting and PCR are the most
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standardized methods. The modified transgenic ES cells are then injected into a
blastocyste originating usually in another mouse strain. The blastocyste is
subsequently transferred into a pseudo-pregnant foster mother. The combination of
cells from both strains within the blastocyte leads to a creation of a chimeric mouse,
what is often reflected by the offspring’s fur colour. After that, the chimeric offspring is
crossed to obtain germline transmission of the targeted DNA to the next generation.
Only then the outcome is successful and results in a mouse that hosts the transgene
in all somatic and germ cells (Williams and Wagner, 2000).
1.6.3. Site-specific transgene insertion
Site-directed genome targeting of a transgene diminishes number of problems linked
to the random approach as discussed in chapter 1.6.1. There are two means of
introducing foreign genes at a specific site: homologous recombination and usage of
site-specific recombinases (SSRs).
Homologous recombination
The mammalian cell is able to support homologous recombination between added
exogenous DNA and the cellular genome on the basis of an exchange between
identical DNA sequences. Selective pressure must be employed to select for this
event as the frequency of homologous recombination is very low (Capecchi, 2005).
Most preferred sites for the recombination of transgenes include housekeeping
genes, whose expression remains constant throughout mouse development
(Bronson et al., 1996).
Hprt, encoding hypoxanthine phosphoribosyl-transferase, is an example of a
housekeeping gene. Hprt is probably the most commonly targeted site in the murine
genome. The Hprt enzyme converts hypoxanthine and guanine into their respective
nucleotides creating a salvage pathway for nucleotide synthesis. Targeting into this
locus permits two modes of selection. Positive selection for a reconstructed,
functional hprt gene involves cultivating the transfected cells in HAT medium
consisting of Hypoxanthine, Aminopterin and Thymidine. While hypoxanthine and
thymidine are sources of purine and pyrimidine respectively, aminopterin blocks the
usual purine and thymidine synthesis routes enforcing the usage of the salvage hprt
pathway. Negative selection against a functional hprt gene activity is based on the
ability of the enzyme to convert purine analogues into toxic nucleotides. Additionally,
localisation of the hprt gene on the X chromosome permits a manifestation of the
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mouse phenotype already after single targeting of the male individual (Caskey and
Kruh, 1979).
Site-specific recombinases (SSRs) (Cre and Flp systems)
SSRs recombine specific DNA sequences with high fidelity and they do not require
any cofactors. Among many different recombinases Cre and Flp are employed in the
genetic manipulation of cells. Cre (Cyclization REcombination) recombines DNA
between two loxP sites in bacteriophage P1, wheras Flp inverts or ‘FLiPs’ sequences
in between two FRT sites in S.cerevisiae   (Branda and Dymecki, 2004).
Recombinases mediate intramolecular reactions of deletion, insertion and inversion,
as well as an intermolecular exchange between different DNA molecules such as
chromosomes. The type of reaction depends on the orientation of the recombinase
target sites loxP or FRT (Fig.1.6). If the target sites are oriented in the same
direction, the recombinase will delete the flanked fragment. If the sites are oriented
opposite to each other, the fragment in between becomes inverted by the
recombinase.
Fig.1.6. Reactions mediated by site-specific
recombinases (SSRs). (modified from Branda and
Dymecki, 2004) (A) Target sites (black arrows)
oriented in the same direction enable deletion or
insertion of the flanked fragment. (B) Two inverted
target sites mediate SSR-mediated inversion.
In case of insertion or deletion, the latter is much more preferred by the enzyme,
what makes it very improbable to introduce DNA fragment in such a way. Therefore,
specific mutations in the target sequences were invented to favour the preferred
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action (Fig.1.7). A recombination between two mutated sites results in the
conformation that is no longer a substrate for the recombinase. The same approach
is applied to ‘freeze’ the preferred conformation after SSR-mediated inversion.
Fig.1.7. Application of mutated target sites for site-specific recombinases. (modified from Branda
and Dymecki, 2004) (A) The modified sites are employed to control the outcome of the recombination.
Upon a reaction between the mutated (two-colour) sites the resulting DNA structure cumulates the
mutations in one of the resulting sites (green). The new conformation is resistant to the recombinase.
The mutations may improve much the efficiency of the stable insertion. (B) The same approach proves
useful for blocking the desired composition of the invertible fragment flanked by two inverted sites.
Site-specific recombinases are widely utilized in transgenesis. Their various
applications comprise site-directed gene knock-out and knock-in, precisely set
chromosomal translocation, as well as the removal of a selection cassette and
intrachromosomal duplication. Recombinases are used to control genes in temporal
and spacial manners. They could be either delivered to a desired tissue at a specific
time point or their expression can be controlled by a promoter which is active in a
certain tissue or during a certain developmental stage (Fig.1.8).
transgene transgene
transgene transgene
transgene
transgene
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Fig.1.8. Application of site-specific
recombinases (SSRs) in tissue-specific
gene in-/activation.  (modified from
Tronche et al., 2002) (A) Activation of a
blocked gene by removal of stop cassette
from between promoter and coding gene,
and (B) SSR-mediated knock-out (deletion
of the gene in between two target sites) may
be both controlled spatially by a tissue-
specific promoter, which controls the
expression of the recombinase.
1.7. Bacterial Artificial Chromosomes (BACs)
1.7.1. BACs as large vectors for DNA delivery
Up to date, there have been three kinds of DNA vectors with an unusual large size
exceeding 30kb: Yeast Artificial Chromosomes (YACs), P1-based Artificial
Chromosomes (PACs) and Bacterial Artificial Chromosomes (BACs). As there is
much to be said about each vector type, I concentrate on BACs, only. All of them are
reviewed in detail by Giraldo et al. (Giraldo and Montoliu, 2001), especially in the
context of transgenic research. The discovery of BACs and PACs was the
consequence of limitations in the application of YACs. Work with the latter requires
special technical skills. Besides, the insert happens to be instable and can undergo
rearrangements within the linear chromosomes. In the end, it can be difficult to purify
them free of endogenous yeast chromosomes (Giraldo and Montoliu, 2001).
BACs are cloning vectors with a mini-F-factor-based replicon as a backbone. This
bacterial replicon maintains a single copy of the recombinant BAC plasmid per cell.
BAC plasmids are genetically more stable than YACs (Wagner et al., 2002). The
cloning capacity of BACs reaches up to 300kb of foreign DNA (Shizuya et al., 1992).
All these features make them especially suited to stably maintain an entire eukaryotic
gene locus together with its regulatory elements. This is especially important for
genes whose regulatory sequences are located tens of kilo base pairs away from
their coding sequence. BACs in comparison to YACs and PACs are more convenient
in handling and they can be easily separated from their E.coli host genome (Marshall
et al., 2004).
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1.7.2. Manipulations with BACs
A number of methods has been established to manipulate BAC plasmids in bacteria.
Most commonly, an exchange between the BAC plasmid DNA and a linear DNA
fragment is based on linear integration, while the allelic exchange between BAC and
a shuttle plasmid employs the ‘chromosomal building’ technique (Wagner et al.,
2002).
For linear integration an antibiotic resistance cassette is required to introduce a
particular mutation into a BAC plasmid (Fig.1.9A). After the linear DNA fragment is
transfected into E.coli, it recombines with the BAC plasmid via the homologous flanks
in the presence of RecA. In the next step the selection marker, which is flanked by
loxP or FRT sites, can be removed by Cre or Flp recombinase as described already
in chapter 1.6.3.
Fig.1.9A. Mutagenesis of BAC plasmids: linear integration. A linear fragment, which encompasses
a mutant allele (∆) recombines via homologous flanks (red and blue) with the wild-type BAC plasmid.
In the second step, the selection marker gene by Cre or Flp recombinase-mediated deletion.
Application of the shuttle plasmid in the ‘chromosomal building’ technique allows
introducing a specific mutation without leaving any operational traces in the
recombinant BAC plasmid (Fig.1.9B).
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Fig.1.9B. Mutagenesis of BAC plasmids: ‘chromosomal building’. Allelic exchange in a process
called ‘chromosomal building’ is based on two steps of homologous recombination. In the first step, a
shuttle plasmid carrying the mutation recombines with the wild-type BAC plasmid via the blue flank,
and a co-integrate is created. The second recombination event takes place via the red flank resulting
in a resolvation of the co-integrate maintaining the mutant allele. If the second recombination occurs
via the blue flank again, the wild-type BAC plasmid is reconstituted. The temperature-sensitive shuttle
plasmid is lost at the non-permissive temperature of 42°C.
First, a shuttle plasmid comprising the mutation is constructed, such that the mutation
of the novel allele is bracketed by two DNA fragments homologous to the wild-type
BAC plasmid sequences located at the site of the desired integration. Allelic
INTRODUCTION
25
exchange between the shuttle and the BAC plasmids takes place by two independent
rounds of homologous recombination in a RecA-assisted manner. In the first
recombination step a co-integrate construct is created, which comprises sequences
from both plasmids. In the second recombination step the co-integrate resolves. If the
second recombination occurs via the homology arm of the first step, the wild-type
BAC is reconstituted. If the second recombination takes place via the other arm, a
mutant BAC is gained (Wagner et al., 2002).
1.7.3. BACs as transgenes
The idea of large DNA fragments as transgenes emerged from the need to overcome
the ‘position effect’ (Giraldo and Montoliu, 2001). This term describes a phenomenon
where host sequences flanking the insertion site of the transgene affect the
transgene’s expression (Wilson et al., 1996). The other advantage that artificial
chromosomes brought into the transgenic field is the opportunity to operate with
complete genes, including their regulatory elements, as described already above.
Transgenic animals carrying large vectors (BACs, PACs, YACs) as transgenes are
generated with efficiencies of 5-20% of newborns, and such efficiencies are
comparable to the standard procedures using small constructs, of less than 30kb as
transgenes (Giraldo and Montoliu, 2001). The copy number of the randomly
integrated BACs and YACs is usually low, not exceeding 5 copies, however, it could
reach as many as 13 copies (Nielsen et al., 1997). Presumably due to the large size
of BAC transgenes a rearrangement or a fragmentation of their sequences can occur
(Giraldo and Montoliu, 2001).
1.7.4. BACs and Herpesviruses
Herpesviruses have the largest genomes among mammalian viruses with up to 200
potential open reading frames (Wagner et al., 2002). Therefore, only the
establishment of BAC technology enabled the universal genetic analysis of these
complex viruses. Many herpesvirus genomes have been already cloned onto a BAC
backbone, including EBV (mentioned already), Herpes Simplex Virus 1 (HSV1),
human Cytomegalovirus (hCMV), Murine g herpesvirus MHV-68 and Kaposi’s
Sarcoma Herpesvirus (KHSV) (Wagner et al., 2002). BAC-cloning of herpesvirus
genomes requires several sequential steps and is described for EBV in Fig.1.10, as
an example. In short, the sequences of the BAC replicon are introduced into a viral
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genome via homologous recombination in the virus-infected cell line. Because the
herpesvirus genome circularizes during replication, it can be isolated as a plasmid
and transferred to E.coli cells, where it can be genetically manipulated (Wagner et
al., 2002). Furthermore, the recombinant viral genome can be packaged into the
virus particles in virus-negative cells upon spontaneous onset or induction of the viral
lytic cycle. After infection with the recombinant virus its phenotype in the host cells
can be analysed (Fig.1.10).
Fig.1.10. BAC-cloning of the EBV genome and its mutagenesis in bacteria. Schematic overview
of the maxi-EBV system. (Delecluse and Hammerschmidt, 2000) After a fragment comprising F-
factor bacterial replicon is transferred into a latently EBV-infected B95.8 B cell line, it recombines with
the genome of EBV resulting in a B95.8/F-factor or maxi-EBV plasmid. The co-integrate is sustained in
the cell line under selective pressure with hygromycin. Upon isolation of the maxi-EBV plasmid from
the cell line and its transfection into E.coli cells, it can be genetically modified in the bacteria. Different
genetic variants of maxi-EBV plasmid can be introduced into the EBV-negative cell line 293 for
packaging into virus particles after initiation of the viral lytic cycle.
This approach opened the opportunity for a detailed genetic analysis of all viral
genes. A combination of the bacterial F-factor replicon with the EBV genome resulted
in an easy to manipulate viral EBV vector (Delecluse et al., 1998). Two different
recombinant EBV vectors have been established: maxi-EBV covers the entire
genome of EBV (Fig.1.11) and mini-EBV contains approximately 40% of the EBV
genome, sufficient to transform primary B cells (Bornkamm and Hammerschmidt,
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2001; Kempkes et al., 1995). Encapsidation of BAC-based EBV vectors has been
improved with the invention of a virus-free 293 packaging cell line hosting an EBV
mutant lacking its packaging signals (Delecluse et al., 1999).
Fig.1.11. The EBV genome cloned onto F-factor bacterial
replicon results in a BAC plasmid, termed maxi-EBV. The
plasmid comprises an entire EBV genome, however, only
latent genes, viral replicon (OriP) and viral terminal repeats
(TR), necessary for virus packaging, are depicted here.
Plasmid backbone includes the F-factor bacterial replicon,
GFP and hyg resistance gene. GFP: green fluorescent protein,
hyg: hygromycin, TR: terminal repeats, OriP: viral replicon,
LMP: latent membrane protein, EBNA: EBV encoded nuclear
antigen.
1.8. Current state of research on EBV
1.8.1. In vitro and ex vivo studies of EBV genes
The majority of the data on the molecular aspects of EBV infection originate from in
vitro studies. Primary human B lymphocytes become growth-transformed by EBV’s
latent gene products and give rise to lymphoblastoid cell lines (LCL) in vitro. Cells
can be either infected directly in vitro or infected cells can be isolated from an EBV-
positive host. Research based on LCLs generated with wild-type or laboratory strains
of EBV has generated a wealth of data on the characteristics of viral DNA and
proteins (Kieff, 1991).
Murine cells expressing human receptors for EBV (CD21 and HLA class II) can be
infected with the virus, although inefficiently leading to the expression of the EBV
latent genes (latency II program) and a long-term persistence of the viral genome
(Haan et al., 2001). Moreover, the characteristic and important feature of EBV to
transform B cells was not shown in this approach. As a consequence this finding has
not led to a murine model for EBV.
1.8.2. Existing in vivo models for EBV infection
Studying EBV in vivo is principally limited to human biopsies and therefore
descriptive. As a result, many topics, in particular latency and oncogenesis, are
hypothetically and controversially discussed (Young and Rickinson, 2004). EBV is a
maxi-EBV
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strictly human virus and does not infect murine cells, what makes it extremely difficult
to establish a model for its pathogenesis. There has been much progress for the last
decades (reviewed in Kuppers, 2003; Young and Rickinson, 2004), which provided
relevant insights into EBV’s biology but many of the important and central questions
remain unsolved.
Human-related species and EBV
Although New World primates are natural hosts for distantly EBV-related viruses,
they are susceptible to EBV in an experimental setting. Cotton top tamarins, a certain
species of New World monkey, develop a lymphoproliferative disease upon EBV
infection, and some even die from lymphoma, but the virus is not transmitted orally
between those animals, and it does not persist in the silenced state in their lymphatic
compartment (Liebowitz, 1998).
EBV-related animal viruses and their natural hosts
EBV together with a related human herpesvirus – Kaposi sarcoma-associated
herpesvirus (KSHV) - belongs to the subfamily of g herpesviruses. Among the animal
herpesviruses from the same viral subfamily particularly two viruses reflect many
aspects of the EBV-provoked diseases upon infection of their natural hosts:
lymphocryptovirus (LCV) in Old World primates (e.g. rhesus monkey, orangutan) and
murine gammaherpesvirus (MHV-68) in mouse.
Old World primates are not permissive to an EBV infection, but they are found
infected with their own species-specific lymphocryptoviruses, which are closely
related to EBV. The cross-reactivity could be responsible for their immunity to EBV.
LCV genomes are highly homologous to EBV and encode a similar range of lytic and
latent genes (Rivailler et al., 2002). Besides, the monkey-LCV model system
reproduced many important features of an EBV infection, from oral transmission,
through activation of peripheral B cells and antibodies production, to latent
persistence of the virus in peripheral blood (Moghaddam et al., 1997). However,
different aspects of disease progression and problems arising from work with such
big animals make these models uncommon for studying EBV biology (Haan et al.,
2001).
An infection with the murine MHV-68 virus is in certain aspects reminiscent of an
EBV infection in humans because both MHV-68 and EBV can activate B cells
evoking infectious mononucleosis syndrome and induce a viral silenced state.
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Furthermore, the MHV-68 sequence is 80% homologous to the EBV genome.
However, the disease phenotypes differ between both viruses (Stevenson and
Efstathiou, 2005) and MHV-68 lacks all homologues for important EBV latent genes
(Haan et al., 2001).
Other animal herpesviruses reconstruct certain aspects of EBV infection. For
instance, rabbits infected with an EBV homologue, Cyno-EBV, develop T-cell
lymphomas with chromosomal abnormalities (Hayashi and Akagi, 2000).
Herpesvirus saimiri (HSV) infects quite a wide range of hosts: from Old and New
World primates to rabbits. In contrast to EBV it can initiate T-cell lymphoproliferative
disease and certain subtypes can immortalize T-cells in culture. Its genome consists
of genes similar to EBV genes but both herpesviruses differ completely in their set of
latent genes (Jung et al., 1999).
Immunodeficient murine models
Intraperitoneal injection of in vitro EBV-infected human B cells into severe combined
immunodeficient (SCID) mice causes lymphoproliferative disease seen in humans
upon EBV infection. Tumours were also observed when the mice were injected with
latently infected B cells isolated from human peripheral blood (Liebowitz, 1998). In a
different model immunodeficient mice (Rag2-/-, gc
-/-) can be engrafted with a human
hematopoietic system and become a model system for EBV. This system can
reconstruct EBV’s entry into B cells, their subsequent proliferation, as well as limited
EBV-specific T cell responses directed against the infected B cells (Traggiai et al.,
2004).
Transgenic mice with single EBV latent genes
Several latent proteins of EBV have been introduced genetically into transgenic mice.
The selected phenotypes  have been already described in the chapter 1.2 and in
Tab.1.1. Studying single EBV proteins in transgenic animals, although informative,
cannot reflect the complexity of a natural viral infection.
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2. AIM OF THE PROJECT
Little is known about the fate of the virally infected cells in the human host and many
aspects of EBV’s life cycle in vivo are not understood. What has also remained
enigmatic is the occurrence of EBV-associated malignancies. To address these
aspects a relevant small animal model system for EBV is required. The mouse is the
most versatile small animal model for different human diseases (Williams and
Wagner, 2000) and this study takes advantage of the well-established techniques of
mouse genetics in order to introduce the complete EBV genome into the murine
genome. This approach would overcome the inability of EBV to infect cells of non-
human origin.
I undertook two routes to insert a genetically altered but otherwise complete EBV
genome into murine cells to assure its stable integration. One route was based on
the site-specific integration into the hprt locus of murine embryonic stem cells. The
other route relied on pronucleus microinjection for random insertion of the EBV DNA
into the genome of fertilized murine oocytes. In both approaches the undifferentiated,
genetically modified mouse cells are transferred into foster mice to give rise to
transgenic offspring. To engineer a recombinant EBV genome for its integration into
the murine genome a special effort was made. This targeting construct (InvTarg)
allows the conditional expression of EBV’s latent genes via a Cre/loxP system. This
approach prevents potentially adverse effects of EBV’s latent genes on embryonic
development but allows their expression in almost any chosen cellular compartment
for which specific Cre-expressing mice are available.
This work is divided into three main parts. The first part (chapters 5.1-5.3)
concentrates on the InvTarg targeting construct, its features, construction steps and
functional analysis. The next section (chapter 5.4) describes handling methods
applied in order to purify and prepare the large Bacterial Artificial Chromosome
(BAC)-based targeting vector, InvTarg, for its introduction into the mouse cells. The
last part (chapters 5.5 and 5.6) describes the many attempts to integrate the linear
InvTarg transgene into the murine genome and the analysis of its integration.
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3. MATERIALS
3.1. Bacterial strains
Strain Genotype Source
E.coli DH5a F-, lacI-, recA1, endA1, hsdR17, D(lacZYA-
argF), U169, F80dlacZDM15, supE44, thi-1,
gyrA96, relA1
(Hanahan, 1985)
E.coli  DH10B F-, mcrA, D  (mrr-hsdRMS-mcrBC),
f80dlacZDM15, D lacX74, deoR, recA1,
endA1, araD139, D(ara, leu)7697, galU,
galK, l-rpsL, nupG)
(Life Technologies)
DH5a strain was a host for small DNA plasmids (up to 20kb), while DH10B was
maintaining BAC constructs.
3.2. Cell lines
Human lines
18 aus 4 human B cell line immortalized with
∆EBNA1-EBV (p2828) integrated in the
genome (donor 18)
(Humme et al., 2003),
Fig.2, lane4
Raji  EBV positive Burkitt Lymphoma cell line (Pulvertaft, 1964)
Wi38 primary embryonic fibroblast cell line (ECACC)
HEK293
TR(-)
embryonic kidney epithelium cells
transformed with adenovirus type 5 and
hosting a maxi-EBV genome lacking its
terminal repeats (EBV packaging cell line)
(Delecluse et al., 1999)
Murine lines
E14TG2a4  (Hooper et al., 1987)
HM1
hprt-negative embryonic stem cell lines, derived
from the 129/Ola mouse strain (Magin et al., 1992)
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3.3. Media
Cell culture media
All human cell lines and primary human B cells isolated from patient samples were
cultivated in RMPI 1640 medium with L-Glutamine (Life Technologies)
complemented with 100mg/ml Streptomycin/100u/ml PenicilinG (Life Technologies),
10% FCS (Biochrom) and 1mM Sodium Pyruvate (Life Technologies). The maxi-EBV
carrying stable line 293 TR(-) was cultured with selection medium with 80mg/ml
Hygromycin B (Calbiochem).
Murine embryonic stem cells were grown in two cell culture media, which differed in
two components:
Composition 1: DMEM (Invitrogen) with 15%FCS (PAN, South America);
Composition 2: Glasgow medium (BHK-21) (Invitrogen) with 10% HyClone FBS
serum (Perbio).
The remaining components were used in common in both media: 1800u/ml ESGRO
(Chemicon), 1.2mM sodium pyruvate (Invitrogen), 1.2mM L-glutamine (Invitrogen),
1.2x non-essential aminoacids (Invitrogen), 0.12mM b-Mercaptoethanol (Sigma).
Transfection media
Opti-MEM (Invitrogen) was used for lipofection and RPMI 1640 (without phenol red
and L-glutamine; PAA Laboratories) for electroporation.
Bacterial media
LB (1% Trypton (Life Technologies) 0.5% yeast extract (Difco Laboratories),
0.5% NaCl)
LB agar plates (15g Bacto-agar (Difco Laboratories) per 1l LB)
SOB (LB with 10mM MgCl2 (Merck) and 10mM MgSO4 (Merck))
SOC (SOB with 20% glucose)
3.4. Oligonucleotides
All the oligonucleotides were synthesized by Metabion.
PCR primers
EES1F17* 5’- AAT ACA TCC AGA TTA AAA TCG CC -3’
EES1B2mod 5’- ATA ACT TCG TAT AAT GTA TGC TAT ACG AAC GGT
AGA AGC CTA GGA ATT ATT TAC CAC ACC CC -3’
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3.4.PCR1 5’- GCT TTC TAC TTC CCC TTT CTA CGC -3’
3.4.PCR2* 5'- TGG CTG GTG ATT GGA GGT TTG -3’
LMP1-F 5'- TCC ATC ATT TCC AGC AGA GTC G -3'
LMP1-B 5'- CTC CTT TGG CTC CTC CTG TTT C -3'
WW-F 5'- AAA GGG TAA CAG GAG AGG CAG G -3'
WW-B 5'- AAG AAG AGG AGG TGG TAA GCG G -3'
LMP2-F 5'- ACG ATG GCG GAA ACA ACT CC -3'
LMP2-B 5'- GCT GGG GGT GTC AAC AAA GAA C -3'
LOX71-F 5'- AAT CGC CAG AAA CAG GAG G -3'
LOX71-B 5'- TTT GTC CAG ATG TCC AGG G -3'
LOX66-F 5'- ATT ACA CCC TTT GCC CCA C -3'
LOX66-B 5'- TGC GTA GCA GCC ACT CTC TAA G -3'
I1-F 5'- CCT GGA CTG GTC TCT CAA TC -3'
I1-B 5'- CTC CTG TTA CCC TTT TAG AAC C -3'
EBNA1-F 5'- CGG GGT CGA GGA GGT AGT G -3’
EBNA1-B 5'- TTC GTC GGT AGT CCT TTC TAC G -3’
(*): used also for sequencing
Sequencing primers
M13rev (Invitrogen) 5´-CAG GAA ACA GCT ATG AC-3´
1.4seq1 5'- CCT TTG TTT TCA ACC TCT TCC G -3’
1.4seq2 5'- CAC CCC AAC TTG TTT ATT GC -3’
1.4seq3 5'- GAT GGA ACA CGA CCT TGA G -3’
2.5seq1 5'- CAG CGC GGG GAT CTC ATG -3’
2.5seq2 5'- GCC ATC CAA AGC ATT CG -3’
2.5seq3 5'- CAG CCT GGG ATA ACA CG -3’
3.4seq1.1 5'- GGT GTG GGC TGT GCG AGT G -3’
3.4seq2.1 5'- TAG CCA TCC AAA GCA TTC G -3’
3162seq1 5'- TGA ATC CTC AAC CCT ATA CC -3’
3162seq4 5'- TCT CCG CCT CAT TCA ATA G -3’
4.3seq-ORI_mut1 5'- TAG AGA ATA GGA ACT TCG GAA TAG -3’
p3299_HPRTpromoter 5'- GGC AGG AGA ATC ACT TGA AC -3’
p3299_ORI_lyt 5'- CAT AGA AAA TCA CCC CAA GTC -3’
p3299neoRflank 5'- AGC GAA ACA TCG CAT CG -3’
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Synthetic oligos
EES101 5’-Pho-TCG AGA TAA CTT CGT ATA GCA TAC ATT ATA
CGA AGT TAT GCT AGC GGA ATG TTA-3’
EES102 5’-Pho-GAT CTA ACA TTC CGC TAG CAT AAC TTC GTA
TAA TGT ATG CTA TAC GAA GTT ATC-3’
3.5. Plasmids
Already established plasmids are listed below and constructs made in this project are
summarized in Tab.1 of Appendix. The established plasmids stem from the collection
of the Department of Gene Vectors, if not specified otherwise. Additionally, the
description of all the plasmids mentioned in this work can be found in the laboratory
database (File Maker Pro, CLONES.FP5).
pBluescript II sk (Stratagene)
pEGFP-C1 (enhanced Green Fluorescent Protein) (Clontech Laboratories)
p2266 (Cre recombinase)
p2670 (pCMV-BALF4)
p288.1 (SV40 early promoter-LMP1) – received from Mary Kay, Madison, USA
p509 (pCMV-BZLF1) (Hammerschmidt and Sugden, 1988)
p995 (disabled replication origin of EBV) (Schepers et al., 1993)
pCP20 (Flp recombinase) (Cherepanov and Wackernagel, 1995)
pCR2.1 (TA-cloning vector) (Invitrogen)
pKD46 (encoding red abg proteins from phage l (redg is arabinose-inducible))
pSV40/Zeo (Stratagene)
p2089 (wild type maxi-EBV) (Delecluse et al., 1998)
p3604 (mutant maxi-EBV plasmid modified at oriP and EBNA1)
3.6. Chemicals and biochemicals
1-Butanol (Roth)
Acetic acid (Merck)
Agarose (Invitrogen)
BSA (New England Biolabs)
Cesium chloride (Sigma)
KH2PO4 (Merck)
L-arabinose (Roth)
NaCl (Merck)
NaH2PO4 (monosodium phosphate)
(Merck)
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Chloroform (Merck)
CIP (Calf Intestine Phosphatase;
alkaline phosphatase) (Promega)
DMSO (Dimethylsulfoxid) (Merck)
DNA Markers (New England Biolabs)
dNTPs (Promega)
EDTA (ethylenediaminetetraacetic acid)
(Merck)
Ethanol (Merck)
Ethidium Bromide (if not specified
Otherwise - Merck)
Glucose (Merck)
Glycerol (Merck)
Glycine (Merck)
HAT (5mM Hypoxanthine, 0.02mM
Aminopterin, 0.8mM Thymidine)
powder, 50x stock (Sigma)
HCl (Merck)
Isopropanol (Merck)
Isoamylalcohol (Merck)
KCl (Merck)
Na2HPO4 (disodium hydrogen
phosphate) (Merck)
NaOH (sodium hydroxide) (Riedel-de
Haen)
Neomycin (G418 disulfate salt) (A1720;
batch: 200mg/ml, 71% active)
(Sigma)
PBS for ES cell culture (Dulbecco’s w/o
Ca&Mg) (PAA Laboratories)
Phenol (Roth)
Potassium acetate (Merck)
SDS (Sodium dodecyl sulphate) (Merck)
Sodium acetate (Merck)
Spermidine (Sigma)
Spermine tetrahydrochloride (Sigma)
Sucrose (MP Biochemicals)
Tris(Tris-(hydroxymethyl)-aminomethan)
(Roche)
Triton X-100 (Merck)
Trypsin-EDTA 1x (Life Technologies)
3.7. Enzymes
Lyzozyme (Sigma)
T4 ligase and 10x T4 DNA Ligase Buffer (New England Biolabs)
Restriction endonucleases (New England Biolabs and MBI Fermentas)
RNaseA (US Biological)
ProteinaseK (Roche)
3.8. Buffers
Church buffer 400mM Na2HPO4, 100mM NaH2PO4, 7%SDS, 1mM EDTA;
pH 7.2
Dialysis buffer 10mM Tris-Hcl pH 7.5, 0.1-1mM EDTA, 100mM NaCl; filter-
sterilized
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Isopropanol saturated with CsCl and water
Microinjection buffer 10mM Tris-Hcl pH7.5, 0.1-1mM EDTA, 100mM NaCl, 30mM
spermine and 70mM spermidine; filter-sterilized
M-stat buffer 0.25mM EDTA, 0.5% Triton X-100, 50mM Tris-HCl pH8, 5%
sucrose
PBS 137mM NaCl, 2.7mM KCl, 4.3mM Na2HPO4, 1.4mM
KH2PO4; pH7.5
SSC 2x 300mM NaCl, 30mM sodium citrate
TAE 1x 40mM Tris-HCl pH8, 5mM NaAc, 1mMEDTA
TBE 1x 89mM Tris, 89mM Borate, 2mMEDTA
TE 1x 10mM Tris pH8, 1mM EDTA
TFB buffer 10mM K-Mes pH6.2, 50mM CaCl2, 45mM MnCl2, 100mM
RbCl
3.9. Laboratory equipment
BioPhotometer (Eppendorf)
Cell culture equipment (hoods (BDK, Heraeus), incubators (Thermo Life Sciences))
Cetrifuges (Eppendorf, Hettich, Sorvall, Kontron), ultracentrifuge (Beckman) with
35ml and 11.5ml tubes (Sorvall)
Electrophoresis (horizontal) chambers: Model B3 (Owl Separation Systems), Model
41-2025-R (Peqlab)
Electroporation unit (Gene Pulser; BioRad) with cuvettes (Peqlab) (2mm - for
bacteria, 4mm - for eukaryotic cells)
FACS machine (FACS Calibur; Becton-Dickinson)
Fluorimeter (DyNA Quant200; Hoefer),
Micropipettes (Gilson)
Microscope (phase contrast and fluorescent) (Zeiss)
3.10 Other materials
Acrodisc Siringe Filters (0.8mm) (Pall Gelman Sciences)
Biomax MS films (Eastman Kodak)
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Folded filters (Schleicher&Schuell)
Human tissue samples (Kinderklinikum Dritter Orden)
QIAEX II and QIAquick Gel Extraction Kits (Qiagen)
Pasteur pipettes (glass) (Roth)
Plastic articles (plates, cryotubes, different tubes) (Falcon, Nunc, Eppendorf,
Hartenstein)
Tooth picks (Forster)
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4. METHODS
4.1. Bacteria culture
Bacteria were cultured either in suspension (LB medium) or on agar plates at the
specified temperatures. Different antibiotic selection was applied at given final
concentrations: 100mg/ml Ampicillin (Sigma), 20mg/ml Chloramphenicol (Merck),
12mg/ml Tetracycline (Merck), 25mg/ml Zeocin (Invitrogen). For long-term storage
bacterial clones were kept in 50% glycerol stocks at –80°C. Bacteria were grown
from the stock on a plate containing the appropriate antibiotics by dilution streaks.
4.2. Cell culture
All cells were cultivated in cell culture incubator at 37°C with 5% CO2. Cell work was
carried out in sterile conditions of a hood, especially important for antibiotic–free work
with embryonic stem cells.
Cells were counted with a Neubauer chamber and living cells were distinguished
from dead ones by a staining with Eosin (0.1% in PBS). Cells were collected by
centrifugation for 5-10min. at 1200 rpm, RT.
Maintenance
293 TR(-) cells, not firmly adherent, were split every 3-4 days. After medium removal
cells were stripped with a stream of a fresh medium, resuspended and plated (1:7).
Adherent Wi38 cells were split twice a week with a 1:5 ratio by trypsynization. All B
cells were cultured in suspension. Raji and EBV-transformed human B cells were
split 1:5 every third day. ‘18 aus 4’ B cell clone was split 1:3 every five days.
Murine ES cell culture was carried-out exclusively with plastic pipettes (Cellstar).
HM1 cells were cultured in ES medium of composition 1, while E14 cell line was
maintained in ES medium of composition 2. The cells were split every second day
with daily medium change. After washing the cells three times with PBS they were
detached with 3min. incubation with Trypsin-EDTA (with 1:100 chicken serum). 106
cells were plated per 10cm dish in 10ml volume. Both ES cell lines were cultivated
without feeder cells, directly on 0.1% gelatine (after equilibration to RT it was added
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for 10-20min. to the dishes (5ml/10cm plate), and subsequently replaced with ES
medium).
Storage
Long-term storage of the cells was carried-out in liquid nitrogen.
For cell freezing a pellet of 107 human cells was resuspended in 1ml RMPI 1640
medium with 10% DMSO and 30% FCS and placed in a 2ml Cryotube (NUNC).
Cells were thawed at 37°C in a water bath for few minutes. Upon adding of the vial
content to 5ml medium, cells were pelleted (1200rpm, 5min., RT) and plated.
The murine ES cells were frozen at 3-5x106 cells per 2ml Cryotube (NUNC) in 1ml of
ES medium complemented with 10% DMSO and 50% ES serum.
Thawing was carried by cryovial incubation at RT for few minutes and the cells were
added to 30ml ES medium. Upon centrifugation (1200rpm, 10min., RT) cells were
plated.
4.3. Molecular biology techniques
The common molecular biology techniques used in the current study were applied
according to standard protocols (Sambrook et al., 1989). The standard methods
included: phenol extraction of DNA and precipitation, measurement of DNA
concentration, enzymatic restriction analysis, DNA dephosphorylation with alkaline
phosphatase (CIP), ligation of DNA fragments, conventional cloning procedures.
4.3.1. Cre (Flp) - mediated deletion or inversion
Cre (Flp) was delivered by transient transformation of the E.coli cells hosting the
given maxi-EBV plasmid with a Cre (Flp)-expressing plasmid, p2266 (pCP20). The
deletion or inversion process was carried out on agar plates o/n at 30°C under
double selection for the maxi-EBV plasmid construct and the Cre (Flp) helper
plasmid. Single, uniform colonies were separated by a dilution streak at 42°C, which
is the non-permissive temperature for the temperature-sensitive helper plasmids,
such as p2266 and pCP20. Subsequent replica plating at 42°C overnight selected
against the Cre (Flp)-helper plasmid and allowed the isolation of clones, which lacked
the helper plasmid.
4.3.2. Dialysis of BAC DNA preparations
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The BAC DNA preparations were dialysed for microinjection and for ES targeting
separately, using microinjection and dialysis buffer, respectively. The DNA sample of
up to 100ml volume was placed on a „V“ membrane (VMWP02500; Millipore) floating
on 5ml of the dialysis (or microinjection) buffer in a 60mm petri dish. The process
was carried for 0.5-2 hours.
4.3.3. Dilution streak of bacteria
Bacteria were streaked with a tooth-stick on one-third of surface of an agar plate. The
next two streaks were done on the rest of the plate, each sourced in the previous
one.
4.3.4. DNA isolation (small and BAC plasmids):
Mini-plasmid preparation
Small plasmids (up to 20kb) – ‘boiling minis’ protocol:
Bacteria were collected with a tooth-pick and transferred to the lysis buffer (200ml M-
stat buffer and 20ml lyzozyme 10mg/ml). The bacteria were suspended by vortexing
for about 30sec. Heating to 100°C in a sand bath for two minutes assured protein
denaturation. Released DNA was found in a supernatant after centrifugation for
10min, at 13000rpm.
BACs (large plasmids exceeding 100kb) - ‘alkaline minis’ protocol:
Bacteria were scraped from an agar plate with a tooth-pick and added to 200ml of 1x
TE with RNaseA (0.4mg/ml). Bacteria were resuspended by vortexing shortly. Lysis
was carried by a mixture with 200ml of a freshly made lysis buffer (0.2M NaOH, 1%
SDS) by sharp and short shaking followed by 3min. incubation on ice. SDS-protein
complexes were precipitated by adding 200ml of Solution III (11.5% acetic acid, 3M
potassium acetate) and mixing thoroughly, gradually increasing the force. After
10min. incubation on ice protein and the precipitate was pelleted at 13000rpm and
2°C for 15min. The supernatant was transferred into a new Eppendorf tube. 400ml
isopropanol were added for precipitation of DNA, which was then pelleted at
13000rpm for 10min. at RT. The pellet was washed with 80% ethanol and centrifuged
again with the same conditions for 5min. After short air-drying DNA was dissolved in
20ml 1xTE.
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Maxi-plasmid preparation
Small plasmids (up to 20kb) – Jet Star DNA Isolation Kit (Genomed), according to the
protocol provided by the company.
BACs (large plasmids exceeding 100kb) – Plasmid DNA was prepared with the
Nucleobond DNA Isolation Kit (Macherey-Nagel), according to the manufacturer’s
protocol.
Highly pure DNA for transfection of eukaryotic cells was prepared with standard
Cesium Chloride-ethidium bromide (CsCl) gradients (in detail below) or with a Qiagen
DNA isolation kit (Large-Construct Kit, or EndoFree Plasmid Maxi Kit).
CsCl Gradient protocol (optimized):
6ml LB medium was inoculated with a single colony in and incubated with the
appropriate antibiotic at 37°C for 6-8h (‘overday culture’). A large size overnight
culture consisted of six 2l flasks shaken at 30°C. Each flask contained 400ml LB,
1ml small ‘overday culture’, 24ml of 5M NaCl and antibiotic at the appropriate
concentration. On the next day bacteria cells were pelleted at 4000rpm, 4°C for
15min. The six pellets were resuspended in 10ml Solution I each (50mM Glucose,
25mM Tris-HCl pH8, 10mM EDTA), and subsequently 35ml of Solution I was
added per bottle. Next, 10mg of lyzozyme powder was added per bottle and the
preparation was vigorously shaken several times and incubated for 10min. on ice.
58ml of Solution II (0.1% SDS, 0.2M NaOH) was added gently per bottle, the
mixture was then mixed while turning up-side-down mildly but thoroughly six times,
and immediately incubated on ice for a maximum of 5 min. To precipitate protein
and cellular debris 70ml of Solution III (11.5% acetic acid, 3M potassium acetate)
was added/bottle, which was then shaken ten times, first slowly and mildly, then
fast and vigorously. Subsequently the bottles were incubated on wet ice for 30min.
up to overnight. Protein and cell debris were pelleted for 20min. at 9000rpm, 4°C.
The supernatant was filtered through gauze, then through paper filters and
collected in 4 centrifuge bottles. At RT, the DNA was incubated for 20min. with
isopropanol (0.7x of volume added). and collected by centrifugation at 9000rpm for
40min. DNA pellet was washed with 80% ethanol at 9000rpm for 30min. at RT.
Once the pellets were air-dried they were dissolved in a total of 40ml 5xTE. 2mg
proteinase K (10mg/ml) was added/bottle and the preparation was shaken at RT
until the DNA precipitate dissolved. The solution was then incubated at 50°C for
1h, 100mg of RNaseA (1mg/ml) was added and the solution was shaken at RT for
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1h. 1 gram of solid cesium chloride (CsCl) was added per 1ml of DNA solution and
dissolved at 37°C (water bath). Ethidium bromide (EtBr) (Roth) was added to a
concentration of around 5%. The DNA-CsCl-EtBr mixture was distributed into two
35ml ultracentrifugation tubes, which were filled to the top with 1.55 g/ml CsCl
solution. Ultracentrifugation was carried for 3-5 days at 38000rpm at RT. DNA
bands from both tubes of the first round of centrifugation were combined into a
new 11.5ml ultracentrifugation tube and the second round was performed under
the same conditions for 2 days. The lower DNA band was harvested and the EtBr
was removed with a (CsCl and water)-saturated isopropanol in Corex glass tubes
in multiple rounds of extraction. DNA was then precipitated with isopropanol and
washed with 80% ethanol at 5000rpm and RT for 1h and 30min., respectively. The
air-dried DNA pellet was dissolved in 100-600ml 1xTE (depending on the pellet
size) and left at 4°C o/n.
4.3.5. Electroelution of BAC DNA fragment
Elution was carried out according to the protocol with Quik-Pik Electroelution
(Stratagene) or GeneCAPSULE (Gbiosciences) capsules. DNA was eluted in Model
B3 chamber (Owl Separation Systems) at 4°C for 1.5h or 20h in 1xTAE buffer.
4.3.6. Electrophoresis
Horizontal large size agarose gel electrophoresis
0.7% agarose gel was run overnight at 70V in 1xTAE buffer. 0.5-1mg DNA/lane was
loaded for an analytical gel (model 41-2025-R electrophoresis chamber).
PFGE
0.6% to 1% agarose gels were run at the following settings: 120°, 6V/cm, 15h, 5-
15sec.,14°C, in 0.5xTBE buffer. The loading was optimized at 0.5mg DNA/lane for an
analytical gel and 3mg of well-dissolved DNA/lane for a preparative gel. (CHEF
Mapper‚ XA Pulsed Field Electrophoresis System; Bio-Rad)
Electrophoresis with other gel chambers was carried out according to standard
protocols.
4.3.7. Electroporation of bacteria
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Electrocompetent bacteria
A bacterial DH10B strain hosting both the appropriate BAC and a temperature
sensitive helper pKD46 plasmid was expanded at 30°C from a single colony, in a
volume of 5ml of an overnight LB culture, under antibiotic selection for both plasmids.
200ml LB culture culture was inoculated with 2ml of the overnight culture and
0.1%(w/v) L-arabinose was added for the induction of Rec proteins expression from
the pKD46 plasmid. The bacteria were incubated for about 4h until OD600=0.3-0.5
was reached. All the following steps of electrocompetent bacteria preparation were
carried out at 0°C with ice-cold 10% glycerol. After the bacteria had been incubated
for 15min. on ice, they were centrifuged at 2°C for 10min. at 7000rpm. After that, they
were washed three times with the glycerol solution in the following steps: the bacteria
pellet was resuspended in 10ml glycerol solution with a cooled pipette, 200ml more
of the glycerol solution was added and bacteria suspension was pelleted at 7000rpm,
at +2°C for 10min. After the last centrifugation step the cells were resuspended in
900ml glycerol solution, and frozen at –80°C for a long-term storage.
Electroporation of DNA fragments
The DNA fragment was generated with appropriate restriction enzymes, purified with
phenol extraction and subsequent ethanol precipitation, and about 2mg was used for
the electroporation. DNA and 60ml of electrocompetent bacteria were combined in a
precooled 2mm wide electroporation cuvette on ice. Immediately after electroporation
(1.9kV, 200W, 25mF) 1ml LB medium was added directly to the cuvette. Bacteria
were transferred to a 15ml tube and incubated while shaking at 37°C for about 2h.
The bacteria were pelleted at 6000rpm for 30sec., resuspended in the rests of liquid
and plated at two different concentrations: 10ml and ‘the remaining volume’. The
plates were incubated overnight at 42°C, the non-permissive temperature of the
pKD46 plasmid, selecting for the recombined maxi-EBV plasmid bearing a double
resistance as a result of homologous recombination.
4.3.8. Enzyme inactivation for BAC DNA preparation
Upon cleavage the restriction enzyme was inactivated for 20min. at 65°C in a heating
block.
4.3.9. Genomic DNA isolation
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Genomic DNA from ES cells and mouse tails was isolated with the Dneasy Tissue Kit
(Qiagen). The procedure was carried according to the manufacture’s protocol.
4.3.10. Homologous recombination in BAC-hosting bacteria
Prior to recombination the BAC-hosting bacteria were stably transformed with the
pKD46 helper plasmid. This ampicillin-resistant plasmid expresses RecA and
RecBCD proteins, which facilitate homologous recombination. Other small plasmids,
cloned in the conventional way, served as a donor of the fragment for homologous
recombination with the recipient maxi-EBV plasmid. The DNA fragment was
electroporated into an appropriate BAC-hosting bacteria strain and selected for the
recombined maxi-EBV plasmid (described in ‘Electroporation’). Dilution streak of the
recombinant bacteria was carried out at 42°C, the non-permissive temperature for
the pKD46 plasmid, to obtain single clones. Subsequent replica plating (42°C,
overnight) identified ampicillin-sensitive and pKD46-free recombinant clones.
4.3.11. Oligonucleotides annealing
The annealing mixture consisted of 1nmol of each oligo and 1x NEB2 buffer (New
England Biolabs) in a total volume of 50ml. The mixture was heated to 75°C to melt
DNA secondary structures and slowly cooled down to about 30°C to allow annealing
and double-strand formation.
4.3.12. PCR
PCR mixture consisted of:            0.5mg DNA template
dNTPs (10mM of each)
1x polymerase buffer (Promega)
primers (100pmol each)
0.25ml GoldTaq Polymerase (5u/ml) (Promega)
in 50ml final volume.
Program 1: 95°C for 3min.
95°C for 45sec.
primers annealing - 53°C for 45sec.
72°C for 2min.
Program 2: 94°C for 2min.
94°C for 20sec.
primers annealing - 56°C for 40sec.
72°C for 2min.
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repeated for 35 cycles
72°C for 10min.
repeated for 30 cycles
72°C for 7min.
The PCR reactions were carried with a PCR robocycler (Gradient 96; Stratagene).
Reaction 1 (part of Step1 of the cloning procedure)
Plasmid template: p288.1 (350ng). Primers: EES1F17 and EES1B2mod. PCR
program 1.
Reaction 2 (part of Step 3 of the cloning procedure)
Plasmid template: 50ng. Primers: 3.4.PCR1, 3.4.PCR2. PCR program 2.
Reaction 3 (genotypic analysis of transgenic mice tails)
Genomic DNA template: 0.5mg. PCR program 1 (with changes: step 1- 5min., step 3-
1min.15sec.). Annealing temperatures: LMP1 primers (59°C), LMP2 primers (57°C),
WW primers (59°C).
Two different positive controls were prepared, such that they mimic a single copy of
the maxi-EBV vector (InvTarg) integrated into the murine genome. The control
samples were composed of genomic DNA from both mES, and human B cell line with
a known copy number of EBV DNA (’18 aus 4’ or Raji). The cell line ’18 aus 4’ carries
3 copies of an integrated EBV genome and Raji carries 50 copies of episomal EBV
DNA. The control samples were named as follows: ‘E-18’ – combination of mES with
’18 aus 4’ DNA, and ‘E-R’ – combination of mES with Raji DNA.
Reaction 4 (genotypic analysis  of mES cells clones)
Genomic DNA template: 0.5mg. PCR program 1 (with changes: step 1- 5min., step 3-
1min.15sec.). Annealing temperatures: LMP2 primers (57°C), I1 primers (59°C),
LOX71 primers (54°C), LOX66 primers (55°C). One positive control, ‘E-18’, was the
same as for the PCR Reaction 3, the other consisted of 30pg 3299.11 plasmid DNA.
4.3.13. Plasmid clone verification
Recombinant plasmids were verified by standard restriction enzyme analysis.
Detailed examination of the introduced features was carried with partial DNA
sequencing.
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Small plasmids (up to 20kb)
Plasmid DNA was purified from bacteria with the mini-plasmid preparation protocol
(see ‘DNA isolation’). The restriction analysis was conducted according to a standard
protocol of DNA cleavage with endonucleases and analysed by a standard agarose
electrophoresis. The parental plasmid served as a reference for the derived
construct.
Once a plasmid clone was identified, it was propagated on a larger scale with a maxi-
plasmid preparation (see ‘DNA isolation’). The plasmid restriction pattern was again
verified with a standard protocol.
BACs (large plasmids exceeding 100kb)
A similar two-step plasmid verification procedure was applied for large BAC
plasmids. Firstly, after DNA was purified with the mini-plasmid preparation protocol
(see ‘DNA isolation’), its restriction pattern was investigated with a standard
horizontal electrophoretical separation overnight. The total preparation obtained with
the ‘alkaline minis’ protocol was digested for 3h with 30u restriction enzyme and
0.5mg RNaseA in 60ml of final volume. Either a wild type maxi-EBV (p2089), or a
plasmid constructed in a previous step served as a reference for the complex
restriction pattern.
Secondly, the correct BAC plasmid clone DNA was then prepared on a larger scale
with the maxi-plasmid preparation protocol (see ‘DNA isolation’). Verification of its
restriction pattern was repeated with this DNA preparation with around 0.5mg
DNA/sample. Critical parts of introduced genetic alterations were directly sequenced
which required sonification of the BAC plasmid DNA.
Highly pure BAC DNA preparations used in transfection of eukaryotic cells were
obtained with the Cesium Chloride Gradient protocol (see ‘DNA isolation’).
4.3.14. Precipitation of DNA (Protocol with ‘FISHing’)
The DNA solution was mixed with 1/10x DNA volume of 3M sodium acetate pH 5.2
solution (Sigma) and 2x DNA volume of 100% ethanol (-20°C cold). The precipitation
mixture was stored at -20°C for a minimum of 30min. up to overnight. DNA
precipitates could be then collected (‘FISHed’) with a flame-closed glass Pasteur
pipette and washed by short immersion in 1ml of 70% ethanol. After air-drying for
approximately 10min. at RT the DNA was dissolved by incubation of the Pasteur
pipette tip in a given solution at RT overnight.
METHODS
47
4.3.15. Replica plating of bacterial colonies
The purpose of this technique was to determine the phenotype of E.coli clones
indicative of their antibiotic resistance. The clone was plated in parallel on two (or
more) plates containing different antibiotics: one, selecting for the desired plasmid
(positive control), and the other (or others), selecting for the unwanted plasmid
(plasmids).
4.3.16. Sequencing
DNA sequencing was carried with given primers by a specialized company
(Sequiserve). Considering BAC constructs, they were sonified and purified by phenol
extraction and ethanol precipitation. About 5mg of the BAC DNA in 1xTE (0.5mg/ml)
was provided for direct sequencing.
4.3.17. Sonification of BAC DNA
BAC DNA (5mg in 200ml TE) was sonified three times for 1sec., at 10% power and
20°C. Sonifier (250-D; Branson).
4.3.18. Southern blotting
Blotting
After separation with a horizontal electrophoresis gel apparatus the DNA bands were
visualized with ethidium bromide agarose gel staining. The marker bands were
marked with ink on the gel, and later the ink dots were transferred with pencil to the
membrane. Prior to the transfer the gel was incubated in 0.25M HCl for 30min., and
subsequently shaked in a Neutralization Buffer (1M NaCl, 0.5M NaOH) for 40min.
The DNA was transferred to a Hybond N+ hybridization membrane (Amersham
Pharmacia) in a capillary manner for 2h (Southern, 1975).
Hybridization
Membrane was prehybridized by rolling at least for 1h up to overnight in Church
Buffer at 60°C. The DNA for probes was stained with [a32P] dCTP (Amersham
Pharmacia) with the High Prime probe staining kit (Roche) and non-incorporated
radioactive nucleotides were removed by gel filtration on NickTM equlibration column
G-50 (Amersham Pharmacia). After heat denaturing of the probe at 95°C for 5min.
followed by a quick cooling step on ice, it was combined with the Church buffer used
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previously. The membrane was hybridized with the probe for 3h (or overnight) by
rolling at 60°C. Unbound probe DNA was washed away from the blot with
0.2xSSC/1%SDS buffer at 60°C. Autoradiography was carried for 30min. up to
overnight, at RT or at –80°C with intensifying screens.
4.3.19. Transformation
Competent bacteria:
Bacteria were cultured in SOB medium until the suspension reached the OD600≈ 0.5.
All the next steps of the preparation were conducted at 0-2°C. Bacteria were pelleted
at 3000rpm for 10min. and the pellet resuspended in 10ml of ice-cold TFB buffer.
Next, bacteria were pelleted again and resuspended in 2.5ml of the ice-cold TFB.
200ml of the competent bacteria were used/transformation sample.
Transformation:
1-10ng of DNA in a maximum of 5m l volume was combined with 200ml of the
competent bacteria. 7m l of DMSO was added/sample and vortexed briefly.
Immediately after the heat shock (2min. at 42°C) 5ml of SOC medium was
added/sample. Transformed bacteria were shaken for 1h at 37°C without antibiotics
for bacteria recovery and phenotypic expression. The cells were pelleted at 3000rpm
for 10min., plated with the appropriate antibiotic and incubated at the given
temperature overnight. Single colonies of transformed bacteria were picked and
expanded for further analysis.
10pg of Bluescript DNA was used as a positive control of the procedure. Negative
controls comprised ligation reaction without ligase or without insert or without DNA.
4.4. Virological assays
4.4.1. EBV packaging into viral particles
Transfection of the EBV packaging cell line with maxi-EBV constructs
The 293 TR(-) packaging cells were seeded on 6-well-cluster plates and transfected
with desired BAC construct. Transfection was carried with Lipofectamine (Invitrogen)
in Opti-MEM medium (OPTI). The conventional cell culture medium was removed
and 1ml of Opti-MEM was added/well and incubated for ca. 30min. BAC DNA was
mixed with OPTI (1mg/0.5ml). Lipofectamine was combined with OPTI (4.5ml/1mg
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BAC/0.5ml OPTI) and both solutions were mixed and incubated at RT for 45 min. To
induce efficient virus production, two expression plasmids: p507 (BZLF1 expressing
vector) and p2670 (BALF4 expressing vector) were co-transfected to the DNA
samples in parallel. 0.5mg of each expression plasmid was added/50ml OPTI, and 6ml
Lipofectamine/1mg DNA was separately mixed in 50ml OPTI. After combination of
both mixtures the solution was incubated for 45min at RT. The OPTI had been
removed from the cells before the DNA-lipofectamine complexes were added (1ml
BAC and 100ml of the expression plasmid mix/each well). Cells were incubated with
the complexes for a minimum of 4h, after which 2ml normal cell culture medium
(without hygromycin)/well was added.
Viral supernatant collection
Three days after transfection supernatants from the transfected 293 cells were
harvested. They were centrifuged at 2000rpm, RT for 1min., filtered with 0.8mm
sterile filter, and stored in a 15ml falcon tube at +4°C.
Verification of the activity of the virus stocks
About 105 Raji cells were infected with 1ml of the virus supernatant, collected in the
previous step, in a volume of about 2ml per one well of a 24-well-cluster plate. On the
second day after infection GFP expressing cells (i.e. cells infected with recombinant
EBV viruses comprising GFP) were counted under a fluorescent microscope, to
estimate the concentration of infectious virions.
4.4.2. Infection of human primary B cells with EBV mutant viruses
Isolation of human B cells from lymphoid tissues (tonsils, adenoids)
The tissue samples soaked in PBS was cut into small pieces with sterile scissors in a
60mm plate, and subsequently strained through a sieve (Cell Strainer, 100mm, nylon;
Falcon) into a 50ml falcon to obtain single cell suspensions. The cells were washed
with 15ml PBS by centrifugation at 1200rpm for 5min. The cell pellet was
resuspended in 30ml PBS and 1ml of defibrinated sheep blood erythrocytes (Oxoid)
were added to deplete T cells in the subsequent step. Peripheral Blood Mononuclear
Cells (PBMCs) were separated from the rest of cells with a Ficoll gradient. The cell
mixture was placed on top of 15ml of Ficoll (GE Healthcare) and centrifuged for
30min. at 1850rpm and 10-15°C. PBMCs were collected from the interphase and
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washed with 15ml PBS in three centrifugation steps: at 1500rpm, at 1300rpm and at
1200rpm. The cells were then resuspended in 2ml medium and counted.
B cell infection with EBV mutant viruses
2x107 isolated B lymphocytes in 5.5ml volume were infected with 5.5ml of the viral
supernatant (1:1 B cells:virus volume ratio) and distributed on a 96-well-cluster plate
(100ml/well) with Wi38 feeder cells (irradiated 5000 Rad/sample). The infected
cultures were cultivated for 4-6 weeks to allow growth transformation of the B cells.
The transformed cells were expanded on new plates without feeder cells.
4.5. Transgenic mouse development
4.5.1. Murine Embryonic Stem (ES) cells targeting
DNA electroporation into ES cells
Fresh medium was added to the ES cells approximately 3h prior to electroporation.
Cells were trypsinized, counted and 2x107 cells were combined with 30mg of plasmid
DNA in 800m l of the transfection buffer (RPMI 1640) and transferred to 4mm
transfection cuvettes. The electroporation conditions were set at 250V and 500mF, if
not specified otherwise. Immediately after the shock 10ml ES cell medium was added
to the transfected cells and they were seeded on 10cm plates.
DNA lipofection of ES cells with Lipofectamine 2000 – optimized protocol
Cells were seeded one day before transfection and plated at a density of 0.5x106/well
of a 6-well-cluster plate. On the day of transfection the medium was exchanged for
fresh medium about 3h prior to transfection. Opti-MEM and Lipofectamine2000
(L2000) (Invitrogen) were equilibrated to RT. Both DNA and L2000 were separately
diluted in 100ml (500ml for BAC) Opti-MEM each (2.5ml L2000/1mg DNA). After 5min.
(max. 30min.) incubation at RT both diluted components were mixed resulting in a
total volume of 200ml (1ml for BAC), and incubated for another 20min. at RT. In the
meantime, the medium from the cells was exchanged for 1ml Opti-MEM/well. DNA-
L2000 complexes were added to the cells in Opti-MEM and incubated overnight in a
37°C incubator (incubation volume – 1.2ml (2ml for BAC)). The transfection medium
was replaced by fresh ES medium on the next day. Selection medium was applied
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when the transfected cells reached about 80-90% density on the second day after
transfection at the latest.
Selection for stably transfected ES cell clones
Selection was started on the second day after the transfection and was maintained
for approximately 12 days. HAT selection medium with a final concentration of
100mM Hypoxanthine, 0.4mM Aminopterin and 16mM Thymidine was applied. For
selection with G418 a final concentration of 350ml/ml was used.
Picking of the targeted ES cell clones
Selected ES cell clones were counted with a grid. Upon double rinse with PBS, they
were picked in 15ml PBS with sterilized 200ml pipette tips set to a volume of 20ml
under a dissecting microscope (Nikon SMZ645). The cell clumps were transferred to
U-bottom-96-well-cluster plates for trypsinization to obtain single cell suspensions.
They were transferred to gelatinized 96-well-cluster plates, one clone/well, and
expanded in the appropriate medium.
4.5.2. Microinjection of BAC DNA into fertilized mouse eggs
The BAC DNA constructs at specified concentrations were handed over to the group
of E.Wolf (Gene Centre, LMU, Munich) for injection into fertilized mouse oocytes
(FVBxFVB). Between 20 to 30 injected oocytes were transferred per a recipient
female. The offspring was kept in the animal facility at the Gene Centre, while the
mouse tail genotypic analysis was conveyed by myself with PCR analysis (chapter
4.3.12).
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5. RESULTS
5.1. Features of the maxi-EBV-based InvTarg targeting construct
Fig.5.1. The InvTarg targeting construct (right) was constructed on the basis of the wild-type
maxi-EBV plasmid p2089 (left). A part of the maxi-EBV genome was inverted and flanked by two
variant loxP sites, which interrupted all latent genes and disabled their expression. The lytic origin of
DNA replication, OriLyt, was inactivated to abrogate accidental release of infectious virion particles. To
permit targeted integration of the linearized InvTarg construct, two sections of the hprt gene are
present. hyg: hygromycin, neo: neomycin, TR: terminal repeats, OriP: viral latent replication origin,
OriLyt: viral lytic origin.
The wild-type maxi-EBV plasmid p2089 was modified in a series of genetic steps to
yield the InvTarg targeting construct p3299.11. The purpose of these genetic
alterations was (i) to disable the expression of all EBV latent genes, (ii) to prevent
formation of infectious virions and (iii) to allow locus-specific integration of the
linearized targeting construct.
To disable latent gene expression, two variant loxP sites were introduced in opposite
directions to allow Cre-mediated inversion of an approximately a 51kb segment
(Fig.5.1). In this work the loxP site oriented in an opposite direction to the loxP wild-
type site is named ‘loxPinv’. The two loxP sites are situated in the InvTarg construct
such that they flank the inversion, which disrupts the transcription units of all latent
EBV genes. A peculiar feature of the Cre/loxP system has to be considered. Cre-
mediated deletion of a loxP-flanked DNA segment is a very efficient unidirectional
process (Fig.5.2a), whereas Cre-mediated inversion is a continuous undirected ‘flip-
flop’ action (Fig.5.2b).
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To ‘freeze’ the state of a desired orientation of the inverting DNA segment, modified
loxP sites, such as lox71 and lox66, are employed (Fig.5.3).
Fig.5.2. Intramolecular Cre/loxP system. Two different genetic configurations can be obtained as a
result of Cre-mediated recombination. (a) Cre can delete a fragment flanked by two loxP sites oriented
in the same direction. (b) Cre can invert a fragment in between two loxP sites oriented opposite to
each other. thick grey arrow head- regulated gene, in yellow - inverted repeats, in red – spacer, small
black arrow - loxP site orientation.
Fig.5.3. Structure of the wild type (loxP), inverted (loxPinv) and mutated (lox71, lox66) lox sites
are shown, which are specific substrates for the Cre recombinase. The inverted repeats serve as
recognition motifs for Cre binding. Lox71/66 ‘locked‘ and wild-type loxP sites are the result of the
recombination of one lox71 and one lox66 site, and the resulting lox71/66 site is refractory to Cre-
mediated reombination. spacer (red) - indicates the directionality of a lox site, flanks - show the DNA
context for the lox sites; mutated nucleotides are shown in lower case and marked with green stars.
After an inversion in between one lox71 and one indirectly oriented lox66 site a
‘locked’ lox71/66 site is created, which is resistant to a subsequent Cre-mediated
recombination, and one wild-type loxP site (Fig.5.4). This feature is a prerequisite for
the one-step re-inversion of the lox71/lox66 bracketed segment in the InvTarg
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targeting construct p3299.11 (Fig.5.1). Re-inversion leads to the activation of all
latent EBV genes after transient expression of Cre.
Fig.5.4. One-step Cre-mediated inversion of the fragment in between lox71 and lox66 sites. The
conformation created upon Cre-mediated inversion is ‘frozen‘ because the lox71/66 site is locked and
thus no longer a substrate for the Cre recombinase. Mutations in the inverted repeats are marked with
green stars.
To assure that there will be no infectious virus synthesized in a murine cell with the
InvTarg construct integrated, the lytic origin of EBV is inactivated in this construct
(Fig.5.1). This aspect is especially important to prevent accidental virus shedding
from a transgenic animal, which would constitute a biohazard.
To permit germ line transmission of the InvTarg construct, it shall be stably integrated
into the mouse genome. Site-specific incorporation into a housekeeping locus, such
as hprt, will sustain faithful maintenance of the transgene in an open chromatin
configuration during development and differentiation (Bronson et al., 1996). Two
flanks, which encompass segments homologous to the murine hprt locus, are part of
the InvTarg targeting construct (Fig.5.1) and shall support hprt-specific
recombination. These two flanks can also complement and reconstitute the disabled
hprt gene in the murine embryonic stem cell line (D hprt mES). A functional hprt locus
on the X-chromosome permi ts  ES cel l  surv iva l  in  HAT
(Hypoxanthine/Aminopterin/Thymidine) selective medium (Szybalski and Szybalska,
1962). In addition, a G418/neomycin selection marker is located opposite to the
reconstituting hprt flank in the InvTarg construct (Fig.5.1). The double selection for
both selective marker genes shall facilitate the integration of the entire InvTarg
construct.
The crucial steps, which were required to introduce numerous genetic alterations in
the InvTarg targeting construct (p3299.11), are described in detail below.
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5.2. Introduction of genetic modifications into the wild-type maxi-
EBV plasmid leading to the InvTarg construct
To make this work more legible, only examples were chosen and presented on the
next pages. Each new feature to be introduced into a maxi-EBV construct was first
constructed in a small plasmid in a multi-step cloning procedure. An example of such
a conventional cloning, provided for a maxi-EBV plasmid modified in the cloning Step
1 (chapter 5.2.1), is described in Steps 1.1-1.3 (chapters 5.2.1.1-5.2.1.3). All other
small plasmids were generated in a similar way. The list of almost 30 plasmid
constructs established during this work is provided in the Appendix.
The genetic characteristics of the InvTarg targeting construct described in the
previous paragraph were introduced into the maxi-EBV wild-type plasmid p2089 in
five consecutive steps (given below).
Each of these five steps encompasses several very specific work packages, which
include the construction of complex features in conventional small plasmids for
modifying maxi-EBV plasmids, introduction of these features into maxi-EBV
plasmids, followed by careful analyses of the genetic modifications. All genetic
manipulations were confirmed in restriction analysis assays (described in the clone
verification protocol in Methods, chapter 4.3.13) and by partial sequencing of the
modified loci. The restriction pattern of the parental wild-type maxi-EBV (p2089) or
the maxi-EBV plasmid from the previous step served as a reference.
A hallmark of this chapter is homologous recombination in E.coli. Two different
techniques were employed for the insertion of the different features into maxi-EBV
plasmids: (1) the ‘chromosomal building’ technique, based on the allelic exchange of
a genetic parental locus to a mutated one between two plasmids, and (2) a technique
called ‘linear integration’, which allows site-specific recombination of a linear DNA
fragment carrying a selectable marker gene. Both methods are described in the
Introduction section (chapter 1.7.2).
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The steps described in this work are listed below and the modifications of maxi-EBV
plasmids are shown in grey:
Cloning step Final plasmid
Introduction of the Cre/loxP system into wild-type maxi-EBV plasmid p2089 to
control the expression of EBV latent genes (Fig.5.5A-C):
Step 1: Insertion of the variant lox71 into into the 2nd intron of
viral LMP1 gene.
p3101.31
Step1.1: PCR-mediated introduction of a lox71 site in the
context of LMP1 gene.
p3060.10
Step1.2: Conventional cloning of a loxP site together with
zeo cassette.
p3064.2
Step1.3: Construction of a floxed (lox71 and loxP) zeo
resistance cassette in the context of the LMP1 gene.
p3071.1
Step 2: Insertion of an inverted loxP site (loxPinv) into the maxi-
EBV plasmid p3101.31 and Cre-mediated inversion
p3125.5
Step 3: Exchange of the loxPinv site of p3125.5 plasmid for the
variant lox66 site.
p3221.12
Introduction of the additional features into maxi-EBV plasmid (Fig.5.11A,B):
Step 4: Inactivation of the EBV lytic origin of DNA replication,
OriLyt within p3221.12 plasmid.
p3283.2
Step 5: Replacement of the hyg  and g f p for n e o and
introduction of hprt flanks for site-specific integration within
p3283.2 plasmid.
p3299.11
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Fig.5.5.A Stepwise introduction of the Cre/loxP system into maxi-EBV plasmids: Step 1.
Introduction of a zeocin resistance gene flanked by lox71 and loxP sites into the second intron of
LMP1 gene by linear integration, followed by Cre-mediated deletion of the zeocin gene. zeo: zeocin.
Fig.5.5B. Stepwise introduction of the Cre/loxP system into maxi-EBV plasmids: Step 2.
Introduction of a zeocin resistance gene flanked by two loxPinv sites into the intron upstream to the Y1
exon of the EBNA-LP gene by linear integration, followed by Cre-mediated deletion of the zeocin gene
and inversion of the lox71/loxPinv flanked EBV segment. zeo: zeocin, loxPinv: inverted loxP.
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Fig.5.5C. Stepwise introduction of the Cre/loxP system into maxi-EBV plasmids: Step 3.
Exchange of the loxPinv site for a lox66 site via ‘chromosomal building’ between p3125.5 maxi-EBV
plasmid and the shuttle plasmid p3213. ts: temperature sensitive replication origin, loxPinv: inverted
loxP.
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5.2.1.1. Step 1.1: Introduction of a lox71 site into LMP1
A PCR product comprising the lox71 site and a part of LMP1 sequence was
introduced into the backbone of the pCR2.1 plasmid. The lox71 sequence was
incorporated at the 5’-end of the oligonucleotide primer EES1B2mod, which was
used together with primer EES1F17 to amplify a part of the LMP1 gene by PCR
(Fig.5.6a). The PCR reaction is described in Methods (Reaction 1 in chapter 4.3.12).
In the next step, the product was cloned into pCR2.1 on the basis of T/A overhangs
(TA Cloning Kit, Invitrogen). This approach did not require a restriction digest of the
PCR product, as the 3’-deoxyadenylate extensions added by the Taq polymerase
during PCR reaction were subsequently combined with the 5’-deoxythymidylate
extensions of the recipient vector. Therefore, after the PCR product was extracted
from an agarose gel, it was directly ligated to the pCR2.1 plasmid DNA. DH5a
competent bacteria were transformed with the ligation mixture and selected for
ampicillin resistance at 37°C. The correct genetic composition of the final construct
p3060.10 was confirmed by the verification procedure (Methods, chapter 4.3.13) and
DNA sequencing with the M13rev primer.
5.2.1.2. Step 1.2: Conventional cloning of a loxP site together with the zeo cassette
An insert encompassing a wild-type loxP site was combined with a zeocin resistant
pSV40/Zeo2 cloning vector (Fig.5.6b). The insert was constructed by the annealing
of two oligonucleotides (Methods, chapter 4.3.11). pSV40/Zeo2 was cleaved with
XhoI and BglII restriction enzymes, dephosphorylated and purified by phenol
extraction and ethanol precipitation. 0.2pmol of the insert was ligated to 0.04pmol
(100ng) of the cleaved and dephosphorylated pSV40/Zeo2 plasmid and transformed
into DH5a competent bacteria, and selected for zeocin resistance at 37°C. The
resulting construct p3064.2 was identified by restriction analysis as described in the
verification procedure (Methods, chapter 4.3.13).
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Fig.5.6. Conventional cloning of the small plasmid, which delivered a fragment for the
recombination with maxi-EBV in the Step1 as shown in Fig.5.5. (a) PCR-mediated amplification of
DNA fragment containing the lox71 site in the context of the viral LMP1 gene, and the PCR product
introduction into the pCR2.1 cloning plasmid resulted in p3060.10 plasmid. The BsaBI/EcoRI fragment
of the p3060.10 plasmid contained lox71 and a part of the LMP1 gene. (b) Arrangement of an oligo
comprising the loxP site with a zeo gene in the SV40/Zeo2 vector. This step gave rise to p3064.2
plasmid, whose EcoRI/BglII fragment comprised both features. (c) BsaBI/BglII fragment of LMP1-
containing p288.1 plasmid, which was used as a backbone for p3071.1 plasmid constructed in the
next step. (d) The final plasmid p3070.1, encompassing the floxed zeocin cassette in the context of
LMP1 gene, was composed of the fragments from both previous cloning steps: (a) and (b), linked to
the segment of p288.1 plasmid (c). Depicted restriction enzyme sites: used in the conventional cloning
(blue) and for producing a fragment for the recombination with the maxi-EBV in Step 1 (red). Flanks
for this recombination are shown in grey. zeo: zeocin.
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5.2.1.3. Step 1.3: Construction of a floxed (lox71 and loxP) zeo cassette in LMP1
The BsaBI/EcoRI fragment comprising the lox71 site (constructed in Step 1.1;
Fig.5.6a) and the EcoRI/BglII fragment encompassing the loxP site assembled with
the zeo gene (Step 1.2; Fig.5.6b) were both combined in a conventional cloning step
with the LMP1 gene of the BsaBI/BglII-cleaved p288.1 plasmid (Fig.5.6c). All three
fragments were extracted from preparative gels, ligated and transformed into DH5a
competent bacteria. The selection was carried at 37°C for zeocin and ampicillin
resistance. The restriction pattern of the resulting p3071.1 construct (Fig.5.6d) was
confirmed in the verification procedure (Methods, chapter 4.3.13)
The MunI/HaeII fragment derived from the p3071.1 construct served for homologous
recombination with the wild-type maxi-EBV plasmid p2089 in Step 1 of the maxi-EBV
cloning procedure leading to the p3080.6 maxi-EBV construct (Fig.5.5A).
5.2.2. Step 2: Insertion of the second loxP site (loxPinv) into the upstream
region of viral EBNA-LP’s exon Y1 and Cre-mediated inversion
Individual steps of this cloning procedure were similar to the steps described in Step
1. A small plasmid p3078.1 was constructed by conventional cloning in E.coli DH5a.
Its zeo gene was bracketed by two inverted loxP sites (loxPinv) and flanked with two
EBV segments (Fig.5.5B). The loxPinv-flanked zeo cassette was arranged upstream
of the Y1 exon of EBNA-LP. The PstI/BbvCI fragment of the p3078.1 construct was
electroporated into the DH10B bacterial cells bearing the maxi-EBV construct
p3101.31 produced in Step 1 (chapter 4.3.10), and bacteria were selected with
zeocin and chloramphenicol for the presence of the p3078.1- and p3101.31-derived
fragments, respectively). The restriction pattern of the obtained maxi-EBV clones was
analysed as described in the verification procedure (Methods, chapter 4.3.13). The
correct composition of the introduced loxP sites in the identified clone p3124.12 was
further confirmed by partial DNA sequencing (Step 2 of Fig.5.7).
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Fig.5.7. Confirmation of the genetic manipulations by DNA sequencing of different intermediate
maxi-EBV plasmids and the final InvTarg targeting construct p3299.11. Each newly introduced
feature was consecutively verified in each step: Step1: Both lox sites and the bordering sequences in
p3080.6 (before Cre delivery), Step2: both inverted lox sites and their bordering sequences in
p3124.12 (before Cre delivery), Step3: lox66 and its flanking regions in p3221.12, Step4: mutation in
lytic origin in p3283.2, Step5: final InvTarg targeting construct was again confirmed for mutated lox
sites (lox71, lox66), disabled lytic origin, and additionally for newly exchanged maxi-EBV‘s F-factor
backbone (hprt flanks and neo introduced). primers depicted in violet, sequenced fragment - thick
black line, zeo: zeocin, oriLyt: viral lytic origin, neo: neomycin.
Subsequently, Cre was delivered into the bacteria hosting the correctly recombined
maxi-EBV construct p3124.12 (Methods, chapter 4.3.1), leading to the removal of the
zeo cassette and to the inversion of the 51kb fragment in between the lox71 site,
introduced in Step 1, and the newly introduced loxPinv. Replica plating allowed the
identification of the clones, which had become zeocin-sensitive upon deletion of the
zeo gene. Cre-mediated inversion in between the lox71 and the remaining loxPinv
site was expected to give rise to two predicted compositions of the newly constructed
maxi-EBV plasmids: p3125.5 - ‘inverted’ (inv) and p3125.3 - ‘NOTinverted’ (NOTinv)
(Fig.5.5B). In the former the fragment in between the two lox sites lox71 and loxPinv
was shown to be inverted as compared to the configuration in the wild-type maxi-
EBV plasmid p2089. Identification of the correctly inverted clones – among them
p3125.3 and p3125.5 – was confirmed by Southern blot hybridization (Fig.5.8). The
designated probes A and B hybridized to sequences surrounding both loxP sites
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(Fig.5.8a). Probe A was the complete p3071.1 plasmid and probe B was the
complete p3078.1 construct (see Appendix, Tab.1). The blot with the hybridized
probe A is presented as an example (Fig.5.8b). On the basis of the Southern blot
experiments with both probes (A and B) the following conclusion was made. The
‘inverted’ clones constituted 15% of all the clones after transient expression of Cre
recombinase, while the ‘NOTinverted’ ones represented 35%. The rest was
composed of mixed (containing a mixture of both inv and NOTinv constructs) and
incorrectly recombined clones. The following steps were pursued with the ‘inverted’
maxi-EBV plasmid p3125.5, after its overall restriction pattern was confirmed
(Methods, chapter 4.3.13).
Fig.5.8. Genetic analysis of the Cre-mediated inversion. Identification of ‘NOTinverted‘ and
‘inverted‘ maxi-EBV constructs with Southern blot technique in the series of p3125 maxi-EBV
plasmids. (a) Probe A hybridized to sequences around the lox71 site generating a pattern of 5.3kb
and 17.2kb for the ‘NOTinverted’ construct, and 8.3kb and 17.2kb fragments for the ‘inverted’
construct. Fragments are obtained with BglII cleavage (in blue). (b) Southern blot analysis of the Cre-
mediated inversion (probe A). Fourteen maxi-EBV-hosting bacterial clones were assessed for the
inversion of the 51kb section in between loxPinv and lox71 sites. The maxi-EBV constructs were
isolated with the mini-plasmid preparation protocol (chapter 4.3.4), cleaved with BglII and blotted. The
8.3kb fragment indicated the ‘inverted‘ configuration as in the p3125.5 (*), while the 5.3kb fragment
identified the ‘NOTinverted‘ maxi-EBV version as in the p3125.3 (**). The 17.2kb fragments are not
shown as they do not distinguish between both orientations. Bands of other sizes represent illegitimate
recombinants as the clones 2,6 and 12.
The latent EBV genes of the p3125.5 maxi-EBV plasmid were disabled as planned
by the inversion of the large DNA segment, which disrupts the coding sequences of
the viral genes LMP1 and EBNA-LP, and abolishes transcription of all EBNA genes
as well as LMP2A. Because this system lacked the means to predetermine the
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outcome of an additional Cre-mediated inversion, the loxPinv site was exchanged for
the variant lox66 site in the next step (Step 3).
5.2.3. Step 3: Exchange of the loxPinv site for the variant lox66 site
To accomplish the exchange of loxPinv versus lox66 the chromosomal building
technique was applied, avoiding the introduction of a selectable marker gene into the
maxi-EBV construct. Two sequential recombination events were required mediated
via two different homologous flanks. First, the shuttle plasmid p3213 was constructed
by conventional cloning and carried the lox66 site flanked by two regions (blue and
red in Fig.5.5C) supporting homologous recombination with the loxPinv locus in the
recipient maxi-EBV plasmid p3125.5. Second, recombination via the blue flank
combined the maxi-EBV recipient plasmid p3125.5 with the shuttle plasmid p3213 to
form a co-integrate of both plasmids (Fig.5.5C). The co-integrate was resolved in
E.coli again through homologous recombination via the red flank. The genetic
manipulations were assisted by expression of RecA from the p2975 helper plasmid in
the recA-deficient DH10B E.coli strain. As an example, the details of the allelic
exchange by the chromosomal building technique are outlined below.
DH10B E.coli cells hosting the p3125.5 maxi-EBV plasmid were transformed
simultaneously with the shuttle plasmid p3213 and the helper plasmid p2975, and
selected for chloramiphenicol, ampicillin and zeocin, (for p3125.5, p3213 and p2975,
respectively) at 30°C. Both shuttle and helper plasmids replicated via a temperature-
sensitive plasmid origin of DNA replication - at 30°C but not at the non-permissive
temperature of 42°C. Plating the transformed bacteria at 42°C and selecting for
chloramphenicol and ampicillin resistance favoured the outgrowth of colonies, which
harboured the expected co-integrate, only (Fig.5.5C). The correct co-integrate was
chosen on the basis of its genetic composition with the verification protocol (Methods,
chapter 4.3.13), and was used in the second recombination step. Again, bacteria
hosting the plasmid co-integrate were transformed with the RecA-helper plasmid
(p2975) and selected for resistance against chloramphenicol and zeocin. The
resolution of the co-integrate was performed overnight at 30°C. This step was
repeated four to five times because spontaneous recombination is very infrequent (1-
3%) even in presence of RecA protein, because no selection pressure could be used
to select for the resolution of the co-integrate. Finally, the temperature was raised to
42°C in the presence of chloramphenicol selection, only, in order to counterselect the
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temperature-sensitive helper plasmid p2975. By replica plating 200 clones were
analysed for sensitivity towards ampicillin, indicating loss of the former shuttle
plasmid p3213 (Fig.5.5C) and resolution of the co-integrate via homologous
recombination. About 15 colonies, which were chlorores/ampsen, were verified by the
verification protocol (Methods, chapter 4.3.13). The identification of maxi-EBV
plasmid, in which the loxPinv site was replaced by lox66, was based on a diagnostic
NheI site, which was only present in close vicinity of the loxPinv site but absent at the
lox66. PCR amplification (Methods, chapter 4.3.12, Reaction 2) encompassing this
region followed by NheI restriction analysis discriminated between both possibilities
(Fig.5.9). The sequence of the newly incorporated lox66 site was confirmed by DNA
sequencing, as shown in Fig.5.7 in Step 3, and the E.coli clone harbouring the
modified maxi-EBV plasmid p3221.12 was chosen for further functional analyses.
Fig.5.9. Verification of the exchange of the loxPinv site versus lox66 in maxi-EBV clones
constructed in Step 3. (a) The NheI restriction cleavage site is situated next to the loxPinv site but
absent at the lox66 site. PCR products, which amplified the relevant region encompassing the variant
loxP sites, were analysed for the occurrence of the NheI site as indicated. (b) Restriction analysis of
the PCR products obtained from sixteen maxi-EBV clones. M: molecular weight marker fX174HaeIII,
C(+): positive control for NheI cleavage (p3125.5 hosting loxPinv); primers are marked in violet.
At this stage the functionality of the Cre/loxP system was evaluated in E.coli. Upon
transient Cre expression in E.coli cells harbouring the maxi-EBV p3221.12, the wild-
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type like conformation of the ‘re-inverted’ p3301 maxi-EBV plasmids (Fig.5.14b) was
predicted to be stabilized by the formation of the ‘locked’ lox71/66 site (Fig.5.4). The
experimental procedure of Cre expression in E.coli cells is described in Methods
(chapter 4.3.1). After Cre expression, the clones were analysed for the inversion
event by restriction analysis (Methods, chapter 4.3.13) (Fig.5.10). Twelve out of
twelve analysed p3301 plasmid clones were ‘re-inverted’; thus the efficiency of re-
inverting the 51kb fragment to the initial, non-inverted orientation was very high, as
expected. Clone 5 of the p3301 maxi-EBV plasmids was employed for the functional
assay of the viral latent gene expression described in chapter 5.3.
Fig.5.10. Cre-controlled re-inversion of the 51kb fragment flanked by lox71 and lox66 sites in
the p3221.12 maxi-EBV plasmid. p3301 plasmid DNAs from twelve bacterial clones were cleaved
with BglII and compared to a maxi-EBV plasmid with the inversion (p3283.2) as negative control (inv).
Clones are numbered from 1 to 12. Yellow arrow heads mark bands indicative of ‘inverted‘ and ‘re-
inverted‘ wild-type like patterns; M: l marker.
5.2.4. Step 4: Inactivation of the EBV lytic origin of DNA replication, OriLyt
The inactivated lytic replication origin of EBV, ∆OriLyt, was introduced by
homologous recombination of a linear DNA fragment with the maxi-EBV plasmid
p3221.12 established in Step 3. The specific mutation in ∆OriLyt is located in the
downstream component of the lytic origin and leads to its complete inactivation, as in
the plasmid p995 (Schepers et al., 1993). This mutation was transferred in a
conventional cloning step from p995 to the small plasmid p3126.1. The NheI/SacI
fragment derived from p3126.1 containing the inactivated lytic origin was used for
homologous recombination (Methods; chapter 4.3.10) with the maxi-EBV plasmid
p3221.12 as schematically shown in Fig.5.11A. The fragment also encompassed a
tetracycline resistance cassette to promote the integration of the fragment into
p3221.12. The resulting maxi-EBV plasmid p3274.7 was validated as described in
the verification protocol in Methods (chapter 4.3.13).
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Fig.5.11A. Inactivation of OriLyt: Step 4. Inactivation of the EBV lytic origin of replication, OriLyt, by
insertion of ∆OriLyt into the p3221.12 maxi-EBV construct. ∆OriLyt was introduced as a linear DNA
fragment together with FRT-flanked tetA gene conferring resistance against tetracycline. Subsequent
expression of Flp recombinase led to deletion of tetA from the p3274.7 intermediate maxi-EBV
plasmid, to yield the maxi-EBV plasmid p3283.2.
Fig.5.11B. Replacement of the F-factor backbone: Step 5. Exchange of the maxi-EBV backbone of
p3283.2 plasmid to replace the selectable marker gene hyg for neo and to introduce two flanks of the
hprt gene to yield the final targeting plasmid InvTarg p3299.11.
Subsequently, the tetracycline cassette in p3274.7 was deleted by Flp recombinase
(Fig.5.11A), which was based on the same principles as the Cre/loxP system
(Fig.5.2). The Flp recombinase removed the section in between two directly oriented
FRT sites upon transient expression. The successive steps of the experimental
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procedure are described in Methods (chapter 4.3.1). Replica plating allowed the
identification of clones that had lost both the tetracycline resistance cassette and the
Flp-expressing plasmid. The resulting recombinant maxi-EBV clones were analysed
in the clone verification manner (Methods, chapter 4.3.13). Their restriction patterns
were compared to that of the p3274.7 maxi-EBV plasmid previous to the Flp-
mediated deletion (Fig.5.12). At this point, the mutation introduced into the lytic origin
was assessed by DNA sequencing (Step 4 of Fig.5.7). The identified maxi-EBV
construct p3283.2 harboured a non-functional viral lytic origin, ∆OriLyt, and reversibly
blocked viral latent genes.
Fig.5.12. Restriction analysis of the p3283.2 maxi-EBV construct with an inactivated viral lytic
origin (conducted in Step 4). (a) The pattern of the previous p3274.7 maxi-EBV construct
(Fig.5.11A) served as a reference. Restriction patterns were verified with three different restriction
enzymes (in blue). (b) List of the visible bands is provided (in kb). Brackets embrace the co-migrating
fragments, which appear as a single band on the gel. M stands for l marker; red colour depicts the
bands, which differ between p3274.7 and p3283.2.
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5.2.5. Step 5: Replacement of hyg and gfp for neo and introduction of hprt
flanks for site-specific integration
The neo gene which carries resistance against G418/Neomycin is the gold standard
in selecting murine embryonic stem cells (mES). Thus, this selectable marker gene
was chosen for the InvTarg construct instead of hyg. In a single step, a series of
events were achieved: the replacement of neo versus hyg, deletion of the gene
encoding GFP and introduction of two hprt flanks (Fig.5.11B). The hprt flanks were
introduced to promote the targeted site-specific integration of the InvTarg maxi-EBV
plasmid in a linear form into the ∆hprt locus of the murine ES cell line. Towards this
end, a conventional small plasmid was constructed in E.coli in a series of cloning
steps (list of intermediate plasmids is provided in Step 5 of Appendix), shown in its
linear form in Fig.5.13. The p3273.1 plasmid was linearized with SacI and
subsequently electroporated into DH10B E.coli cells hosting the maxi-EBV p3283.2
(the construct of Step 4), and selected for tetracycline and chloramphenicol (for
p3273.1 fragment and p3283.2 plasmid, respectively) as described in Methods
(chapter 4.3.10). The resulting maxi-EBV recombinants were analysed for their
genetic composition by the verification procedure (Methods, chapter 4.3.13).
The identified maxi-EBV plasmid p3299.11 (InvTarg) bore the Cre-controlled switch,
the inactivated viral lytic origin and features for the targeted site-specific integration
into the hprt murine locus via hprt flanks and the selectable marker neo. This InvTarg
plasmid p3299.11 was sequenced at all the important, genetically manipulated sites
(Step 5 of Fig.5.7).
Fig.5.13. Structure of the conventional small plasmid used for recombination with the recipient
maxi-EBV plasmid in Step 5. The small plasmid p3273.1 contained a number of features for
introduction into the maxi-EBV construct p3283.2 via linear integration (through the EBV homologous
flanks): neo, the neomycin resistance cassette, two hprt flanks, and the F-factor replicon containing
FRT-flanked tetA resistance gene. PacI restriction sites allowed linearization of the final InvTarg
targeting construct deleting the bacterial F-factor replicon.
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5.3. Functional analysis of the conditional EBV latent genes switch,
a core feature of InvTarg construct
The InvTarg maxi-EBV plasmid p3299.11 I constructed (chapters 5.1 and 5.2) bears
a unique switch, which allows the activation of almost all viral latent genes upon
expression of Cre. The construct is ‘off’ meaning that the maxi-EBV cannot express
its latent genes and is therefore incapable of growth transforming primary human B
cells. On the basis of this read-out the function of Cre-recombinase to activate the
latent genes by re-inversion was verified. Four different maxi-EBV constructs were
tested: p3125.3, p3125.5, p3221.12 and p3301.5. The maxi-EBV plasmids p3125.3
and p3125.5 were obtained in Step 2 during the construction of the InvTarg plasmid
(Fig.5.5B). They constitute an isogenic pair, which differs only in the orientation of the
loxP-flanked EBV segment. In p3125.3 the segment is oriented as in wild-type maxi-
EBV (Fig.5.5B, p3125.3 NOTinv), but the segment is inverted in p3125.5 (Fig.5.5B,
p3125.5 inv) inactivating EBV’s latent genes. Both plasmids carry one loxP site
(loxPinv) and one variant lox71 site. The remaining two maxi-EBV plasmids,
p3221.12 (Fig.5.5C) and p3301.5 (not shown) also form a pair which differs with
respect to the orientation of the EBV segment: p3221.12 has its latent genes
disabled but p3301.5 corresponds to the situation in wild-type maxi-EBV. The latter
was derived from the former by transient expression of Cre in E.coli as described in
chapter 5.2.3.
All four maxi-EBV plasmids were packaged into EBV virions as described in Methods
(chapter 4.4.1) and human primary B cells were infected (Methods, chapter 4.4.2).
Four to six weeks post infection the infected B cells were assayed for their capacity
to yield lymphoblastic cell lines transformed by EBV. The data provided in Fig.5.14
proved that only maxi-EBV plasmids, which had the loxP-flanked segment in wild-
type conformation gave rise to transformed B cells, as expected. The data also
document that the genetic alterations in particular the introduced loxP sites did not
interfere with the transforming capability of the maxi-EBVs.
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Fig.5.14. Functional analysis of the Cre-mediated switch of EBV latent genes with four maxi-
EBV plasmids. The maxi-EBV plasmids were packaged into EBV viral particles and primary human B
cells were infected with these viruses. (a) The loxP sites introduced in plasmid 3125.3 (NOTinv) did
not interfere with B-cell transformation process, while the inversion in p3125.5 (inv) interrupted viral
latent genes expression. (b) The same held true for the constructs hosting lox66 instead of loxPinv.
The ‘inverted’ construct p3221.12 (inv) did not transform B cells, while the p3301.5 (re-inv) plasmid
after re-inversion supported B cell proliferation. (c) Wild-type maxi-EBV served for a positive control in
the experiment. It is capable of transforming B cells and does sustain their proliferation. The negative
control comprised uninfected B cells, which died within 1-2 weeks post infection. (d) Relative
transformation efficiency of all four plasmids was calculated from four independent experiments
carried for each plasmid. The unexpected but low ability of the ‘inverted’ constructs to stimulate B cell
proliferation was most probably linked to contaminating EBV field strains present in the primary human
B cell preparations, because the transformed B cells lacked the GFP expression. B cell proliferation
was assessed with light microscopy, GFP expression was visualized with UV fluorescent microscope.
5.4. Linearization and further processing of the InvTarg construct,
prior to introduction into murine cells
5.4.1. Preparation and purification of the InvTarg plasmid DNA from E.coli
 In order to introduce large maxi-EBV DNA into murine cells the quality of the DNA
preparation must be improved, in terms of purity and intactness, as compared to the
procedure of genetic manipulations in E.coli. Three different methods of maxi-EBV
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plasmid DNA purification were tested: alkaline lysis followed by cesium
chloride/ethidium bromide (CsCl)-gradient preparation (detailed protocol in Methods,
chapter 4.3.4) and two Qiagen kits: EndoFree Maxi Plasmid and Large-Costruct kit.
The DNA quality was assessed by PFGE. Two different maxi-EBV constructs, of
about 185kb in size, were employed in the assay: p2089, a wild-type maxi-EBV, and
p3299.11, the InvTarg targeting construct (Fig.5.15).
Fig.5.15. Comparison of
different methods for large
maxi-EBV DNA preparation.
Two dif ferent maxi-EBV
plasmids were purified and
assessed by PFGE: p2089, a
wild-type maxi-EBV, and
p3299.11, InvTarg targeting
construct. Maxi-EBV DNAs
were cleaved with a given
enzyme and 0.5mg of each
digestion was loaded per lane
of a pulse field gel (although it
was calculated to load the
same amount of linearized
DNA per one lane, the
amounts dif fer between
preparations as the DNA
concentration was not always
accurate). p2089 DNA was
purified with Qiagen EndoFree
Maxi Plasmid Kit and linearized
with SgfI (ENDO). p3299.11
was isolated either with the
CsCl-gradient protocol (CsCl)
or with Qiagen Large-Costruct
kit (LC) and cleaved with PacI.
M: MidRange marker.
The constructs were linearized with restriction enzymes as indicated. According to
evaluation by PFGE, the quality of the maxi-EBV DNA preparations from all the
protocols was comparable, but DNA obtained via CsCl-gradient was superior in
terms of quantity.
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5.4.2. DNA integrity of the InvTarg construct
Standard restriction analysis of large maxi-EBV plasmids cannot assess their
molecular integrity because conventional vertical electrophoresis does not allow
proper verification of DNA fragments exceeding 30kb but a pulse field gel
electrophoresis (PFGE) allows separation of very large DNA molecules (Fig.5.16a).
Fig.5.16. Electrophoretic analysis of digested InvTarg p3299.11 DNA. (a) The same preparation of
p3299.11 BAC plasmid was either digested with the frequently cleaving BamHI enzyme and run on a
conventional horizontal agarose gel (0.5mg/lane), or cleaved with PacI (two fragments of 185kb and
9.1kb are expected) and loaded on PFGE gel (1mg/lane). Only the latter method revealed the poor
quality of the 3299.11 DNA preparation. (b) The optimal loading capacity per one lane of PFGE gel
was 3mg/lane of PacI-digested 3299.11 DNA. M: MidRange marker, l: l-BstEII marker, PFGE: Pulse
Field Gel Electrophoresis.
To aid the isolation of the 185kb band of the linearized InvTarg plasmid, the practical
loading capacity of a single lane on a PFGE gel was experimentally determined.
Although it was possible to load as much as 15mg of 3299.11 PacI-cleaved DNA per
one lane, a characteristic smear appeared indicating overloading (Fig.5.17a, lane1).
Therefore, 3mg of well-dissolved 3299.11-PacI DNA per lane was found to be optimal
(Fig.5.16b).
5.4.3. Linearization of InvTarg plasmid DNA
In the following step the InvTarg targeting construct was linearized, which was
mandatory to allow its chromosomal integration, because linear DNA molecules are
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preferred in both random (Giraldo and Montoliu, 2001) and site-specific (Capecchi,
2005) transgene integrations. After digestion of the InvTarg plasmid p3299.11 with the
PacI restriction enzyme, the 185kb targeting fragment was purified by PFGE. To test
the excision of this fragment from a single lane of PFGE gel (for its subsequent
electroelution with Quik-Pik kit), cleavage of different amounts of DNA in small volume
was evaluated. Different 3299.11 DNA amounts were cleaved overnight with PacI in
80ml volume, which was then separately loaded on a PFGE gel (Fig.5.17a).
Fig.5.17. Optimization of long-term PacI digestion of p3299.11 InvTarg plasmid. (a) p3299.11
maxi-EBV DNA was cleaved with 5u PacI in 80ml overnight and the whole digest was loaded on single
lanes of PFGE gel. Samples differed in DNA amount taken for each cleavage: 1 - 15mg, 2 - 12mg, 3 -
10mg, 4 – 8mg. (b) 0.5mg from each of the four PacI-cleaved samples was digested with HpaI and run
on large conventional horizontal agarose gel. Presence of 6.7kb and 4.7kb bands in PacI/HpaI
cleavage indicated complete cleavage with PacI. (c) Overnight cleavage of 1mg 3299.11 DNA in 80ml
volume was carried with 2u of PacI enzyme, and subsequently loaded on a PFGE gel (two samples
cleaved in the same conditions). M: MidRange marker.
Complete digestion with PacI was verified with the subsequent cleavage with HpaI
(Fig.5.17b). As indicated by the presence of the PacI/HpaI specific fragments in this
double cleavage, all the PacI digestions were complete. These results indicated that
as much DNA as 15mg could be cleaved to completion with as little enzyme as 5u
PacI (0.3u/mg DNA), but very high amounts of DNA loaded on single lanes of the
PFGE gel were not optimally separated during electrophoresis (smear along the
lanes; Fig.5.17a).
The effect of increased PacI concentration during overnight digestion on DNA quality
was also investigated (Fig.5.17c). After 1mg of 3299.11 DNA was cleaved with 2u
PacI (2u/mg DNA) in 80ml, its linearization was estimated with an analytic PFGE gel.
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The higher enzyme concentration did not increase the usual level of DNA
degradation (smear between 185kb and 9.1kb bands).
Shortening of the digestion time was also investigated for the 3299.11 cleavage with
PacI. 1mg of 3299.11 maxi-EBV DNA was digested for 4h in 80ml with 8-15u (8-
15u/mg DNA) of PacI, and the DNA quality was estimated with a PFGE gel (Fig.5.18).
The cleavage conditions did not reveal an increase in DNA degradation.
In the next experiment, lowered enzyme concentration was verified in the same
cleavage reaction. As a result, 3mg of 3299.11 DNA was cleaved to completion in
80ml within 4h with 10uPacI (3.3u/mg DNA), only (Fig.5.19, lanes 3 and 4).
Fig.5.18. Optimization of sort-term PacI
digestion of p3299.11 InvTarg plasmid DNA.
Different amounts of enzyme were compared in
terms of DNA quality (two samples/condition).
1mg of p3299.11 DNA was digested for 4h with
8u or 15u of PacI in 80ml volume. DNA was
subsequently separated on a PFGE gel. M:
MidRange marker.
In the final conclusion from the digestion experiments, optimal conditions for the
complete cleavage of the 3299.11 DNA with PacI, without overdigestion, were set.
They differed between the long-term overnight digestion (in average 16h) and the
short-term digestion for 4h, and are summed up in Tab.5.1. The ratios of the PacI
concentration to DNA concentration were calculated to set the final range of the
border-line concentrations of the enzyme that can cleave DNA completely without
causing its degradation.
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Tab.5.1. Optimal cleavage conditions for the InvTarg plasmid DNA. The border-line
concentrations of PacI enzyme for p3299.11 DNA cleavage, which led to the complete cleavage
without overdigestion, are specified for long-term (overnight) cleavage and short-term digestion (4h).
Ratios of the enzyme concentration to the DNA concentration set for both border-line settings delimit
the range of the optimal cleavage conditions, allowing easy comparison of each next digestion to the
optimized reactions.
5.4.4. Further processing of the linearized InvTarg DNA
In order to purify transgene DNA prior to introduction into murine cells, after digestion
with PacI the 3299.11 the InvTarg construct was processed in four different ways: (i)
the enzyme was inactivated (ii) followed by dialysis, (iii) the DNA was directly
precipitated or (iv) the 185kb fragment was electroeluted from a preparative PFGE
gel. The quality of the DNA upon each procedure was assessed on an analytical
PFGE gel.
(i)and (ii): Enzyme inactivation and dialysis of the InvTarg plasmid preparation
In order to prevent an influence of an active PacI restriction enzyme on the
subsequent transfection and injection procedures, the enzyme was heat-inactivated
according to the procedure described in Methods (chapter 4.3.8). In the second
approach the PacI-digested DNA was dialysed after the enzyme inactivation with the
intention of adjusting salt concentration of the DNA preparation prior to its
introduction into mouse cells. Dialysis was conducted against a microinjection buffer
for the microinjection purpose, or against a buffer suitable for the transfection into ES
cells. PFGE analysis revealed that the linearized maxi-EBV 3299.11 DNA did not
become degraded upon enzyme inactivation and/or subsequent dialysis in
comparison to DNA, which was ‘simply’ cleaved (without further processing)
(Fig.5.19).
Cleavage time Overnight 4h
Enzyme concentration Minimum PacI Maximum PacI Minimum PacI Maximum PacI
Cleavage conditions
in 80ml volume
5u PacI for
15mg DNA
2u PacI for
1mg DNA
10u PacI for
3mg DNA
8 to15u PacI for
1mg DNA
Ratio of
PacI concentration (u/mg DNA)/
DNA concentration (mg/ml)
0.3 Pac/
187 DNA
= 0.0016
2 Pac/
12.5 DNA
= 0.16
3.3 Pac/
37.5 DNA
= 0.088
8 to 15 Pac/
12.5 DNA
= 0.64 to 1.2
Range of optimal cleavage
conditions
0.0016-0.16 0.088-1.2
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Fig.5.19. Enzyme inactivation and dialysis of the linearized InvTarg p3299.11 targeting
construct. 1mg of p3299.11 DNA was cleaved with PacI and run on a pulse field gel. DNA was loaded
directly after cleavage (1), after enzyme inactivation (2, 3), and after enzyme inactivation with
subsequent dialysis (4). Samples 1 and 2, as well as samples 3 and 4 were prepared in parallel. M:
MidRange marker.
(iii) Precipitation of InvTarg construct DNA
Prior to chromosomal integration targeting vectors are most commonly precipitated
after linearization in the first step towards establishing a transgenic mouse. Linear
DNA of the size of the InvTarg maxi-EBV plasmid is very fragile and therefore
sensitive to this treatment. Particularly, once linearized, it is vulnerable to mechanical
breakage due to its large size. Two different approaches of DNA precipitation
following the linearization were tested: the standard protocol and precipitation ‘with
FISHing’ (described in Methods, chapter 4.3.14). The DNA pellet was resuspended
either in the appropriate buffer for microinjection or in 1xTE for ES transfection. The
standard precipitation most often led to DNA degradation (Fig.5.20a), while the
alternative precipitation protocol ‘with FISHing’ predominantly resulted in mostly
intact linear DNA molecules (Fig.5.20b).
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Fig.5.20. DNA precipitation of the linearized InvTarg p3299.11 targeting construct. p3299.11
DNA digested with PacI was directly precipitated with either the standard precipitation protocol (S) or
the precipitation protocol ‘with FISHing’ (F). The PacI-digested 3299.11 DNA treated with an enzyme
inactivation (In) served as a positive control for the DNA quality. Loading: 1mg/lane (a), 300ng/lane (b).
M: MidRange marker.
 (iv) Electroelution of the 185kb InvTarg targeting fragment after PFGE
Isolation of a targeting fragment from a transgene construct is advantageous
because this fragment can be directly enriched. Moreover, contaminating bacterial
DNA, the plasmid backbone and degraded plasmid DNA can be all omitted.
Following linearization with PacI the 3299.11 InvTarg DNA was run on a preparative
PFGE gel. The fragment of 185kb was excised and subsequently electroeluted from
the gel according to the Quik-Pik protocol (Methods, chapter 4.3.5). The eluted
fragment was dialysed against the appropriate buffer for microinjection. Electroelution
was successful, high quality of the linear targeting maxi-EBV vector was produced
(Fig.5.26, samples 1-4). However, recovery of the linear maxi-EBV DNA in this
approach was very low as expected, and it underwent degradation within around two
weeks of storage at +4°C. Therefore, it was impossible to exploit this method for DNA
transfection into murine ES cells.
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5.5. Site-specific insertion of InvTarg construct into murine ES cells
The murine ∆hprt embryonic stem (ES) cell lines (HM1 and E14) are characterized
by an inactivated hprt gene on the Y chromosome. hprt can serve as a selection
marker because hprt-negative cells cannot survive in HAT (Hypoxanthine,
Aminopterin and Thymidine) medium as described in chapter 1.6.4 of Introduction.
The hprt locus of ∆hprt ES cells can be restored with an appropriate targeting
construct, which promotes homologous recombination with the hprt- allele and
introduces a suitable promoter with first two exons of hprt (Fig.5.21).
5.21. Reconstruction of the disabled hprt locus in ∆hprt murine ES cells. The DNA targeting
construct complements the deleted hprt locus with an hprt human promoter, human first exon and
murine exon two located all on the right flank of the linearized construct. The left flank of the transgene
recombines with the upstream region of the hprt locus providing the second selection marker gene,
neomycin (neo). The construct can recombine with the hprt locus via homologous recombination
(dashed lines). (a) PacI-linearized InvTarg maxi-EBV construct p3299.11 (185kb) introduces a
recombinant EBV genome, with conditional viral latent gene expression, together with the neo
selection cassette. (b) 20kb control targeting construct carries the neo gene. neo: neomycin, hprt:
hypoxanthine phosphoribosyl-transferase, WW: viral repeats, ∆OriLyt: disabled viral lytic origin of DNA
replication; hprt promoter and its nine exons are shown in blue, bidirectional arrow heads indicate
homologous regions. Figure not drawn to scale.
The InvTarg maxi-EBV targeting construct, when cleaved with PacI, provides the
missing hprt parts with its right flank. The left flank of InvTarg carries sequences
homologous to the upstream hprt locus in conjunction with a second selectable
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marker gene – neo, encoding resistance against G418 antibiotic. Both flanks bracket
the genetically altered but complete EBV genome. Introducing this DNA transgene
into ∆hprt ES cells should promote its homologous recombination and result in cells,
which can survive selection with both HAT and G418.
5.5.1. Optimization of murine ES cells transfection
Because transfection of such a large linear DNA molecule as the InvTarg maxi-EBV
plasmid constitutes a challenging task, the conditions of the procedure were first
assessed with a smaller (20kb) control plasmid – p3162, equipped with neo
resistance and hprt flanks for integration into the hprt locus of Dhprt murine ES cells
(Fig.5.21b). As a prelude, transfection conditions for HM1 cell line were assayed with
a small GFP plasmid and the most favouring conditions were chosen in transient
transfection experiments. Two different electroporation conditions were tested in this
experiment with the pEGFP-C1 plasmid: 250V, 500mF (E-1), 800V, 3mF (E-2)
(Tab.5.2).
Tab.5.2 Initial optimization of the
transfection conditions for the HM1 Dhprt
ES cell line. This experiment was based on the
transfection of the small GFP plasmid, pEGFP-
C1, into two samples of HM1 cells cultured
under different conditions and transfected with
two different electroporation settings: HM1-1- in
DMEM medium, HM1-2- in Glasgow medium,
E-1- 250V and 500mF, E-2- 800V and 3mF. The
readout was evaluated under light (survival)
and fluorescent (GFP) microscope. The results
shown represented the percentage of GFP-
positive cells of 107 cells plated.
Additionally, the HM1 cells were cultured in two different media, DMEM (HM1-1) and
Glasgow (HM1-2), both complemented with FCS (PAN), to test which culture
conditions favour successful DNA uptake and cell survival. 2x107 cells were
transfected with 30mg of the GFP-encoding plasmid, pEGFP-C1, and half of the
transfected cells were plated on 3 (for E-1) or 4 (for E-2) 10cm plates. The efficiency
of DNA uptake was evaluated on the second day after transfection. HM1 ES cells
cultured in Glasgow medium (HM1-2) showed better survival and transfection
efficiency than cells cultured in DMEM medium (HM1-1) (Tab.5.2). Milder
electroporation conditions (E-2) led to improved cell survival but resulted also in a
much lower transfection efficiency: 0.6% of the transfected cells expressed GFP after
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E-1 transfection, in contrast to 0.08% after E-2 transfection for HM1-2 culture
conditions.
In order to further improve the efficiency of the ES transfection procedure, different
Dhprt ES cell lines, HM1 and E14, and two distinct transfection and selection
methods were tested in a single experiment targeting the hprt locus with the control
plasmid p3162 (Tab.5.3).
Tab.5.3 Further optimization of
Dhprt ES cells targeting with the
small targeting plasmid p3162.
Three transfection conditions were
tested with the p3162 plasmid
carrying neo  resistance and hprt
homologous flanks. Two different
Dhprt ES cell lines were investigated:
E14 and HM1. The cells were either
electroporated (250V, 500mF) or
transfected with L2000 (Invitrogen
protocol), and subsequently selected
with HAT alone, or first with G418
followed by HAT medium (G418 Æ
HAT) medium. The readout is
presented in x10-4% of the number of
colonies with respect to cells
transfected init ially (106 f o r
lipofection, 107 for electroporation),
and represents the average from two
experiments.
In a first approach, 2x107 cells were electroporated with 30mg PacI-linearized p3162
plasmid DNA and seeded on four 10cm plates, which were selected differently. One
half was selected with HAT medium and the other half was selected first with G418
for one week and subsequently with HAT medium alone. In a second approach, the
linearized p3162 plasmid was transfected with lipofectamine 2000 (L2000) according
to the manufacture’s protocol (Invitrogen). 4mg of this DNA was transfected per 106
cells (in one well of a 6-well cluster plate). Four ES cell samples were transfected in a
single experiment. Two samples were put under selection with HAT medium and the
other two were selected first with G418 and then with HAT medium alone. The
results of these experiments are summarized in Tab.5.3. The E14 ES cell line
showed a 2-6 fold better targeting efficiency than the HM1 cell line. Transfection with
L2000 appeared to yield improved results in comparison to electroporation by a
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factor of 5-18. Sequential selection with G418 followed by HAT medium alone (G418
Æ HAT) resulted in a 3-9 fold higher efficiency than selection with HAT medium, only.
In conclusion, lipofection of the E14 ES cell line and sequential G418 Æ  HAT
selection were employed in the following transfections.
The original lipofection protocol from Invitrogen was altered in an attempt to further
improve ES cell targeting with the linearized p3162 construct. Minor changes in the
original Invitrogen protocol did not alter the targeting efficiencies as detailed in
Tab.5.4, but further modification of several parameters resulted in an improvement
(Tab.5.5).
Tab.5.4. Initial optimization of the E14 ES cells transfection with lipofectamine 2000 for the
PacI-linearized p3162 control plasmid. Several transfection conditions (listed on the left side) were
changed in comparison to the original protocol for transfection with Lipofectamine2000 (L2000)
provided by Invitrogen (shown on the right side). 4mg of PacI-linearized p3162 was lipofected per 106
E14 cells with the Invitrogen protocol, which were then selected first with G418 then in HAT medium
(G418 Æ HAT). Transfection results are given in colony number per 106 cells transfected, and are the
average from three separate samples. 6-well - one well of the 6-well plate, RT – room temperature,
Opti-MEM – serum free medium, a.t.: after transfection.
Conditions, which were expected to increase the transfection and targeting
efficiencies included higher concentration of DNA with Lipofectamine2000 (DNA-
L2000) complexes and a lower volume of the serum-free medium for the incubation
of cells with the DNA-L2000 complexes. Time for incubation of cells with the DNA-
L2000 complexes also affected ES colony formation (Tab.5.5). In conclusion, the
final conditions were: 106 E14 ES cells, 1mg PacI-cleaved p3162 DNA, DNA-L2000
complexes incubated in 0.2ml of serum-free medium (Opti-MEM), and the incubation
of cells with the complexes in 1.2ml of Opti-MEM overnight (‘optimized protocol’
specified in detail in Methods, chapter 4.5.1).
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Tab.5.5 Standarization of the transfection protocol with lipofectamine 2000 for the PacI-
linearized p3162 control plasmid. The optimized lipofection protocol (shown on the right side)
originated in the initial Invitrogen protocol. One more transfection condition was additionally tested and
its variations are given on the left side of the table. 106 E14 ES cells in one 6-well were lipofected with
Lipofectamine2000 (L2000) and with 1mg of PacI-linearized p3162 plasmid following the optimized
protocol (detailed in Methods, chapter 4.5.1). Variations in the incubation time of cells with the DNA-
L2000 complexes led to different results in terms of colony formation under G418 selection followed by
HAT selection (G418 Æ  HAT). Transfection results are given in colony number per 106 cells
transfected and as average from 2-5 separate samples. 6-well - one well of 6-well plate, RT – room
temperature, Opti-MEM – serum free medium.
Summing up the experiments aiming at optimization of the ES cells transfection
procedure the following conclusions were made. Although transfection of HM1 cells
was optimized (Tab.5.2), it did not reach the targeting efficiencies achieved with the
other ∆hprt ES line, E14 (Tab.5.3). Most favourable targeting conditions for the E14
cell line were chosen: transfection with Lipofectamine2000 (L2000) and selection with
first G418 for a week followed by HAT containing selective medium (Tab.5.3). An
improved protocol for E14 transfection with L2000 was established in a series of
optimization experiments (Tab.5.4 and Tab.5.5).
5.5.2. Transfection of the linearized InvTarg construct into murine ES cells
Because the size of the linearized maxi-EBV targeting plasmid InvTarg is 185kb as
compared to the much smaller test plasmid p3162, uptake of DNA of that size was
investigated in transient transfection experiments with murine ES cells. The InvTarg
maxi-EBV plasmid p3299.11 lacks a simple phenotypic marker such as gfp,
therefore, I used a different maxi-EBV plasmid, p3604, for the initial transient DNA
transfections. This plasmid was digested with either SgfI or AscI to cleave it once or
twice in the following conditions: 10mg DNA in 200ml with 5u AscI or SgfI for 15h. The
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quality of the cleaved DNAs was assessed with PFGE (Fig.5.22a). 3mg of the linear
DNA molecules, upon cleavage with SgfI or AscI, were transfected with the
developed protocol with Lipofectamine2000 (L2000) into 106 E14 ES cells (chapter
5.5.1) with adjustments for the large BAC plasmids (‘optimized protocol’ for BACs, in
Methods, chapter 4.5.1). The adjustments were made to adopt transfection
conditions for large BAC plasmids established in my laboratory (D.Pich, personal
communication). Two different methods, UV-fluorescent microscopy and FACS
analysis, were applied to assess the transfection efficiencies in ES cells. The ES
cells were successfully transfected with the GFP-encoding maxi-EBV plasmid
(Fig.5.22b) and the transfection efficiency was estimated to be about 15% on
average (Fig.5.22c). The largest 185kb fragment produced by SgfI cleavage of p3604
entered the cells with 2% reduced efficiency as compared to the 110kb fragment
obtained after digestion with AscI (Fig.5.22c). However, the efficiencies were most
probably overestimated for the linearized large BAC plasmid, as cellular uptake of
smaller DNA fragments containing GFP was also recorded. Therefore, the
efficiencies of BAC transfections are further called ‘relative’, and the aim of these
experiments was a preliminary optimization of transfection of large linearized DNA
plasmids with a simple visual assessment.
Several transfection experiments with the test plasmid p3162 suggested a correlation
between the number of successfully targeted ES cells and the amount of DNA
transfected or concentration of L2000 used (data not shown). This observed
correlation for large maxi-EBV plasmids was verified separately with the linear p3604
plasmid, as the size of the DNA molecules could have an influence on the outcome.
The p3604 maxi-EBV plasmid was cleaved with AscI (10mg DNA in 200ml with 5u
AscI for 15h), ‘enzyme inactivated’ (Methods, chapter 4.3.8) and verified with PFGE
(Fig.5.22a). Different amounts of DNA were transfected with different amounts of
L2000 into E14 ES cells (‘optimized protocol’ for BACs, Methods, chapter 4.5.1). The
results are shown in Fig.5.23, indicating that an increase in DNA or L2000
concentration slightly improved the relative DNA uptake but the relative transfection
efficiency could not be further improved with up to 9mg DNA (Fig.5.23b). Within single
experiment the same DNA preparation was used for different conditions of
transfection.
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Fig.5.22. ES cells are transduced with large maxi-EBV DNA plasmids. (a) Quality of the digested
and ‘enzyme inactivated’ p3604 DNA was assessed on a PFGE gel; 0.5mg DNA was loaded per lane.
Each cleavage produced fragments of discrete lengths: AscI - 110kb and 76kb, SgfI - 185kb. M -
MidRange marker. (b) 3mg of p3604-AscI (a, lane2) was lipofected into E14 ES cells with
Lipofectamine2000. (c) FACS readout of E14 cells lipofected with 2.5ml/mg DNA of L2000, and with
3mg of p3604 cleaved with SgfI (180kb fragment; a, lane1) or 3mg of AscI-cleaved p3604 (110kb and
76 kb fragments; a, lane2). Untransfected cells served for a mock control. Results are shown in
percentage of GFP-expressing cells in gated ES cell population. Detection of GFP with fluorescent
microscope and FACS (2x104cells/sample) were performed about 24h post transfection (b, c). PFGE:
Pulse Field Gel Electrophoresis, GFP: green fluorescent protein.
In summary, transient transfection experiments with E14 ES cells and large maxi-
EBV plasmids were assessed with two independent methods. Higher concentration
of the transfecting agent (L2000) was not toxic for the transfected cells with 15ml
L2000 per 106 cells and 6mg DNA transfected. The efficiency of transfecting 106 cells
with 3mg DNA and 7.5ml L2000 differed between 9% and 16% in distinct experiments,
which was probably related to different DNA preparations. In the final conclusion, the
amount of 180kb long DNA fragment for transfection into 106 E14 cells was set 3-6mg
with 2.5ml L2000/mg DNA.
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Fig.5.23. Conditions for optimal transfection of ES cells with linearized large maxi-EBV plasmid
DNA. AscI-cleaved p3604 DNA (Fig.5.22a, lane2) was transfected into 106 E14 ES cells with
Lipofectamine2000. (a) Untransfected cells were used as a negative control (MOCK). (b) Different
amounts of L2000/mg DNA (3mg DNA transfected/sample) (c) and various DNA amounts/sample (2.5ml
L2000/mg DNA) were examined. FACS analysis was conducted about 24h post transfection
(2x104cells/sample). Transfection efficiency is given in percentage of GFP-expressing cells in the
gated ES population. L2000: Lipofectamine2000, GFP: green fluorescent protein.
Finally, the maxi-EBV targeting construct p3299.11 was cleaved with PacI, purified
and transfected into E14 ES cells under optimal conditions (Methods, chapter 4.5.1,
‘optimized protocol’ for BACs). The cleavage conditions for the InvTarg plasmid were
set within the optimized range (Tab.5.1), and additionally, the quality of the linear
DNA preparation in each sample was verified on a PFGE gel as exemplified in
Fig.5.19 for enzyme inactivation and dialysis, and Fig.5.20 for precipitation of DNA.
Transfections were done many times, as summarized in Tab.5.6. The amount of
DNA transfected ranged in between 3-6mg/106 cells, as optimized in transient
experiments with maxi-EBV DNA (Fig.5.22 and 5.23). The transfection protocol
differed slightly between the trials in reference to the ‘optimized protocol’ in order to
increase the precentage of surviving cells; either the incubation time of cells with
DNA-L2000 complexes was shortened from overnight to 4h or the amount of
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transfected cells was doubled. Two different selection modes were applied: HAT and
a combination of HAT and G418.
Unfortunately only one round of lipofections yielded a single ES cell colony that
survived selection with HAT, only (Tab.5.6). The single ES cell clone, which arose
from this experiment, was subjected to further analysis described in the next chapter
(5.5.3).
Tab.5.6 Summary of ES cell transfections with the PacI-linearized maxi-EBV targeting plasmid,
InvTarg. Successful targeting conditions of a single HAT-resistant clone are provided in the first lane
(Reference). Overview of 9 different transfections with the variations in different relevant parameters is
given below, with the similarities to the reference conditions depicted in green. E14 cells were
transfected with Lipofectamine2000 (L2000) with slightly different transfection protocols: A – optimized
(Methods, chapter 4.5.1, protocol for BACs), B - incubation time of cells with DNA-L2000 complexes
was shortened to 4h, and followed by medium change, C – 2x106 ES cells transfected/sample.
Selection medium with HAT, or with HAT and G418 combined (HAT+G418). Each transfection
conditions were tested in 1-6 separate experiments.
TransfectionNo
Protocol DNA
 (mg/106 cells)
Selection No of samples
(106cells/ sample)
Enzyme inactivation:
Reference A 6 HAT 6
(1 colony out of 6x106
transfected cells )
1 A 3 HAT 16
2 A 6 HAT 12
3 A 6 HAT+neo 18
Enzyme inactivation+Dialysis:
4 B 3 HAT 10
5 B 5 HAT 16
Ph FISH:
6 A 6 HAT 6
7 A 6 HAT+neo 6
8 C 6 HAT 34
9 C 6 HAT+neo 48
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5.5.3. PCR analysis of the hprt+ ES cell clone targeted with the InvTarg
construct
The analysis was based on PCR verification of the targeting construct InvTarg in the
hprt locus of the ES cell clone, which survived selection with HAT medium. Different
PCR primer pairs were designed to detect relevant parts of the integrated linear
maxi-EBV p3299.11 DNA (Fig.5.24, in blue). The region containing the two loxP sites
and viral WW repeats was especially important for verification, because it was
functionally relevant for the Cre-mediated activation of the EBV latent genes by re-
inversion of the loxP-flanked segment. Therefore, three primer pairs were set in this
region: lox71, WW and lox66. PCR products from the other two primer pairs (LMP2
and EBNA1) shall indicate whether left and right end of the linear 3299.11 transgene,
respectively, were integrated in the ES cell genome.
Fig.5.24. Schematic presentation of the InvTarg maxi-EBV targeting construct p3299.11 in the
mouse hprt gene locus and its detection by PCR. Horizontal line represents the PacI-linearized
intact p3299.11 construct integrated into the genome of the ∆hprt ES cell line, E14. PCR-mediated
amplifications of relevant genetic loci in transgenic mice (upon microinjection, described in chapter
5.6) are depicted in violet, while the ones used in PCR with ES cell template DNA are shown in blue.
DOriLyt: mutated lytic origin of EBV, neo: neomycin, gene encoding resistance against G418, ES:
embryonic stem cells;
The one HAT-resistant ES cell clone targeted with the InvTarg maxi-EBV construct
was examined for the presence of the EBV sequences. On the basis of the extensive
PCR analysis I found that only the region of WW repeats was integrated into the ES
genome (Fig.5.25). The selection conditions revealed the presence of a functional
hprt gene but no resistance against G418 selection, suggesting that the neo
resistance cassette was also absent. Apparently, only fragments of the InvTarg maxi-
EBV targeting construct were integrated resulting in the functional restoration of the
hprt gene.
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Fig.5.25. PCR analysis of the integrated InvTarg targeting construct p3299.11 in the HAT-
resistant ES cell clone. DNA from targeted E14 ES cells was used as template for PCR reaction with
different primers (schematically shown in Fig.5.24). M: f marker, H: HAT resistant ES clone, (-):
negative, water control, ES: E14 genomic DNA, negative control, (+): positive control: genomic DNA
containing EBV (E-18)  - for LMP2 and I1 PCR, and 30pg 3299.11 DNA - for LOX71, 66 and EBNA1
primers. PCR conditions and the positive controls are described in Methods (chapter 4.3.12, Reaction
4).
5.6. Random integration of linearized InvTarg construct upon
microinjection
Microinjection of the large BAC DNA into fertilized mouse eggs is an alternative
method to establish transgenic mice. In contrast to the targeted integration into a
certain predetermined locus, chromosomal integration of foreign microinjected DNA
molecules is a random and uncontrolled process.
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5.6.1. Microinjection of the linearized InvTarg construct into fertilized murine
oocytes
PacI-linearized InvTarg p3299.11 DNA was prepared with different protocols and its
quality was assessed with analytical PFGE gels (Fig.5.26). The digestion conditions
were set within the optimized range (Tab.5.1).
The linear 3299.11 DNA was electroeluted, ‘enzyme inactivated’ or precipitated
(Methods, chapter 4.3.5, 4.3.8. and 4.3.14, respectively). DNA concentrations of the
eluted samples were estimated on a pulse field gel by comparison with a quantitative
molecular weight markers. The concentrations of 3299.11 DNA in the ‘enzyme
inactivated’ and precipitated samples were calculated from the input DNA used for
the cleavage or by employing spectrophotomeric measurements. The prepared
InvTarg targeting construct was microinjected into fertilized oocytes of the FVBxFVB
mice strain (Methods). A total of eight injection trials led to surviving offsprings in only
one round. All results are summarized in Tab.5.7.
Fig.5.26. Preparation of the PacI-linearized p3299.11 InvTarg DNA for microinjection.
Preparations of 3299.11 DNA used in the procedure are numbered according to microinjection dates.
The same numbering system was applied in Tab.5.7. DNA was digested with PacI, treated in the
indicated way (Tab.5.7) and run on a pulse field gel. Loading: 1/10 to 1/2 of the eluted sample/lane -
samples 1-4, 250ng/lane – samples 5 and 6, 1mg/lane – sample 7, 150ng/lane - sample 8. M:
MidRange marker, quantitative markers: l-Bst: l-BstEII, l-Hind: l-HindIII.
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Tab.5.7. Overview of all microinjection trials of the InvTarg targeting construct p3299.11-PacI
into fertilized oocytes. Summary of all the injections provides information on how and when
p3299.11 DNA was prepared, at which concentration it was injected and what the result was in terms
of trangenic mice delivery. DNA preparations used in the procedure are numbered according to
microinjection dates and refer to the numbers of DNA samples shown in Fig.5.26. overnight: overnight,
fm: foster mother, Ph FISH: DNA precipitation with ‘FISHing’.
5.6.2. PCR analysis of mice born from oocytes microinjected with the InvTarg
construct
The five mice, which successfully survived oocyte injections and the one still-born
mouse obtained in the course of microinjection 1 (Tab.5.7) were analysed by PCR for
the presence of the integrated maxi-EBV DNA p3299.11. The localization of the PCR
primer pairs is shown in Fig.5.24. Only parts of the viral WW repeats region were
detected in the five mice alive (Fig.5.27, lanes 1-5), while unfortunately only the still-
born mouse had all the investigated regions inserted (Fig.5.27, lane 6).
DNA
RESULT
No
Time
between
cleavage and
injection
(days)
Further
processing
Injected at
concentration
(ng/ml):
Foster
mothers
transferred
(with injected
embryos)
Embryos
did not
develop in
uterus
Embryos
died in
uterus
Born mice
1 14 Electroelution 2 2fm - - 1fm - 5 alive
(partly
transgenic),
1fm - 1  dead
(transgenic);
2 5 Electroelution 0.25 2fm 2fm - -
3 7 Electroelution 0.25 1fm 1fm - -
4 12 Electroelution 0.25 1fm 1fm - -
5 4 Enzyme
inactivation
0.25 1fm - - 1 died after
birth (from
1fm);
6 5 Enzyme
inactivation
0.25 1fm 1fm - -
7 5 Enzyme
inactivation
0.5 2fm
&
1fm
2fm
&
1fm
-
-
-
-
8 2 Ph FISH 0.25 4fm 2fm 2 from 1fm,
1 from 1fm
-
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Fig.5.27 Detection of microinjected linear p3299.11 DNA in mouse genomic DNA by PCR. DNA
from mouse tails was employed as template for PCR reactions with different primers (schematically
shown in Fig.5.24). 1 - 6 - DNA from six mice; M: f marker, (-): negative, water control, (+): positive
control: genomic DNA containing EBV (E-R for PCR on EBNA1, E-18 - for the rest of samples). PCR
conditions and the positive controls are described in Methods (chapter 4.3.12, Reaction 3).
Summing up the Results section, the p3299.11 maxi-EBV conditional plasmid,
InvTarg, has been constructed, and its Cre-mediated switch regulating EBV’s latent
gene expression was functionally tested in primary human B cells. The optimal
conditions for linearization and further purification of the InvTarg plasmid DNA were
chosen, and the experimental settings for the targeting of the hprt locus of the murine
ES cells with the small control plasmid p3162 were optimized. However, both the
transgenic ES cell lines targeted with InvTarg targeting vector, and the transgenic
mice obtained upon microinjection with the same construct had only subgenomic
pieces of the InvTarg transgene integrated.
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6. DISCUSSION
Much information has been already gathered on EBV in vitro and different in vivo
models for EBV exist but a complex animal model for the EBV-related diseases is still
lacking. The experimental work of my thesis identified critical aspects of the steps
towards a murine model system for EBV. The experience gathered here creates the
basis for the next steps to the final goal. The proposed model would provide the
complex environment of a living organism for studying the function of EBV.
Additionally, the application of a sophisticated molecular switch governing EBV’s
latent genes can open more possibilities to study the biology of this virus.
6.1. InvTarg maxi-EBV targeting construct
The maxi-EBV InvTarg vector has been constructed on the basis of the established
wild-type maxi-EBV plasmid p2089, a large Bacterial Artificial Chromosome (BAC)
vector comprising the complete genome of the prototype EBV strain B95.8
(Delecluse et al., 1998). In my project, I first constructed the targeting construct
InvTarg (p3299.11) in E.coli. The many necessary genetic alterations to construct the
final maxi-EBV plasmid, InvTarg, were based on common genetic techniques
developed in E.coli (reviewed in Wagner et al., 2002). A series of recombinant
conventional and maxi-EBV plasmids had to be established and many different steps
were needed to precisely introduce the planned genetic modifications. The
techniques utilized in the construction of the large BAC plasmids are described in
Introduction (chapter 1.7.2).
Two variant loxP sites were introduced into the wild-type maxi-EBV vector to control
viral latent genes expression indirectly via a Cre recombinase-mediated genetic
switch. The Cre/loxP system is widely applied in genetic research as described
already in chapter 1.6.3 of Introduction. Furthermore, Cre was reported to invert large
DNA fragments (Campo et al., 2002). The main feature of the InvTarg targeting
vector is an inversion of a segment of EBV’s genomic DNA with respect to the
parental wild-type plasmid p2089, which disables the expression of almost all the
latent EBV genes. The inversion of 51kb was made possible by two loxP sites, which
bracket the inverted segment. Upon transient expression of Cre recombinase latent
gene expression can be activated in that Cre mediates re-inversion of the loxP-
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flanked EBV segment. Because Cre functions in every cell, latent EBV genes can be
switched on at will. A stabilization of the ‘re-inverted’, activated conformation of
EBV’s latent genes is possible due to two variant and asymmetric loxP sites: lox71
and lox66 (Fig.5.4). Upon Cre-mediated re-inversion, a mutated loxP site is created,
lox71/66 ’locked’, which is no longer a substrate for the recombinase. A similar Cre
system, which is based on these two variant loxP sites was already applied for one-
directional inversions (Oberdoerffer et al., 2003; Zhang and Lutz, 2002).
Two additional genetic features were introduced into the InvTarg targeting construct.
In order to prevent accidental production of the infectious virus in murine cells or
transgenic mice, EBV’s lytic origin of DNA replication was disabled. Because
spontaneous virus production is possible in EBV-infected cells (Bornkamm and
Hammerschmidt, 2001). The housekeeping locus of hprt murine gene assures
ubiquitous and constitutive expression of the integrated transgene (Bronson et al.,
1996). Therefore, flanks for a site-specific homologous integration into the murine
hprt locus were added, to insert the maxi-EBV targeting vector into an active gene
locus.
It was very important to assess the function of the Cre-mediated switch and to
confirm that the introduction of two loxP sites did not interfere with the expression of
crucial latent EBV genes. The latent genes of EBV are engaged in B cell
transformation in vitro (Murray and Young, 2001). The Cre-mediated switch was
functionally assessed in primary human B cells (chapter 5.3). Precursors of the
InvTarg targeting plasmid, i.e. maxi-EBV plasmids with a functional viral origin of lytic
replication were used. Four maxi-EBV plasmids, which constitute two pairs, were
engineered in Step 2 and 3 as described in chapter 5.2 and Fig.5.5B,C. Two
plasmids, p3125.3 and p3125.5, carry lox71 and loxPinv sites, and the remaining two
constructs, p3221.12 and p3301.5, bear lox71 and lox66 sites. EBV latent gene
expression is blocked in p3125.5 and p3221.12 because these maxi-EBVs
encompass the ‘inverted’ conformation, whereas latent genes are active and in wild-
type, i.e. ‘re-inverted’ conformation in p3125.3 and p3301.5. All maxi-EBV precursor
plasmids were separately packaged into EBV viral particles in a helper packaging cell
line and the virions were subsequently used to infect B cells. Upon infection with the
wild-type EBV B cells become transformed, only when the essential set of viral latent
genes are expressed. Thus, the wild-type and ‘re-inverted’ constructs growth-
transformed B cells as expected, while maxi-EBVs with the ‘inverted’ configuration
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did not lead to an outgrowth of B cells (Fig.5.14, chapter 5.3). Thus, expression of
Cre recombinase permits the spatial and temporal control over crucial viral latent
genes.
The Cre-mediated switch of the EBV latent gene expression was introduced into the
InvTarg targeting vector in order to avoid a potential adverse impact of the viral latent
gene products on mouse development. Additionally, this approach enables activating
all latent genes in different cell compartments and at distinct time points by cross-
breeding with specific Cre-expressing mice, so-called deleter mice. Cre-deleter mice,
which express Cre in a certain cellular compartment, only, are available now in many
different cell types and even different stages of cellular differentiation (Metzger and
Feil, 1999). Crossing these mice with an EBV-transgenic mouse would allow the
exclusive expression of EBV’s latent genes in T cells, epithelial cells of the
oropharyngeal or gastric epithelium, for example.
Because EBV’s impact on other cell types but B lymphocytes has not been well
defined (Young and Rickinson, 2004), the controlled expression of the EBV latent
genes in those other cells could possibly show their role in the cell transformation.
It is uncertain whether EBV provokes tumours in humans directly through the
expression of its gene products, its integration into the host genome or indirectly
initiating cellular genetic lesions (Kuppers, 2003). This issue arose from the
observation that EBV is absent in certain percentage of the tumour cells in many
EBV-associated diseases (Tab.1.3). A modified version of the InvTarg vector, in
which the viral latent genes become inactivated upon Cre expression, might indicate
whether EBV genes have a role in maintaining the state of a transformed cell.
6.2. Introduction of the InvTarg targeting vector into murine cells
Two technical approaches were used to stably introduce the InvTarg targeting
construct p3299.11 into murine cells as a prelude to an EBV-transgenic mouse: (1)
pronucleus microinjection of the EBV construct into a fertilized oocyte, and (2) ES cell
genome targeting. In both cases, the manipulated mouse cells in their
undifferentiated state shall give rise to transgenic animals upon their implantation into
the uterus of a foster mother. The site-specific approach of the ES cells-based
technique has the advantage of circumventing random insertional mutagenesis,
which is common in microinjected oocytes (Williams and Wagner, 2000). Problems
can arise from neighbouring sequences, which might have an unforeseeable impact
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on the accidentally inserted transgene (reviewed in Introduction, chapter 1.6.1). The
ES cell-based transgenic mouse development is considered to be ‘more
sophisticated and demanding’ (Williams and Wagner, 2000). Both transgenic
techniques were applied in the current study in order to complement each other to
increase the chance of success in this ambitious project.
Considering the targeting vector, conditions for both locus-specific insertion into the
mouse genome and subsequent expression of the vector-encoded genes have to be
fulfilled. Hasty et al. demonstrated up to nine-fold better ES targeting efficiency with
so-called, ‘insertion vectors’ in comparison to ‘replacement vectors’ (Hasty et al.,
1991b). The ends of the linearized ‘insertion vectors’ are homologous to the
sequence at the targeted site, while ‘replacement vectors’ are linearized outside of
the region of homology. My InvTarg targeting vector p3299.11 is an ‘insertion vector’;
thus, the double-strand break within the region of homology should increase the rate
of insertion considerably (Orr-Weaver et al., 1981). The length of homologous flanks
of the p3299.11 construct is also within the optimal range: 3.4kb and 7kb. Both flanks
should assure efficient homologous recombination, as fragments of more than 2kb
suffice and longer ones (up to 7kb) increase the efficiency of the insertion (Hasty et
al., 1991a). The original EBV promoters included in the integrated maxi-EBV InvTarg
construct are expected to control EBV gene expression after its integration into the
murine chromosome. There are two indications, which presume the active state of
EBV promoters in mouse cells. Two EBV’s latent genes, LMP1 and LMP2, were
reported to be expressed upon introduction of an episomal maxi-EBV vector
comprising all EBV genes into murine ES cells (H.Herrmann, personal
communication). However, only three latent genes were analysed in total. Besides,
the EBV latency II program was shown to be expressed in EBV-infected murine B
cells carrying the human surface receptors for EBV (Haan et al., 2001) but here
again expression of the latent EBV genes was restricted.
6.2.1. Bacterial Artificial Chromosome (BAC) as a transgene
My maxi-EBV targeting construct, InvTarg, which is based on a bacterial mini-F
backbone and contains the entire EBV genome, belongs to the family of large
Bacterial Artificial Chromosomes (BACs). There are several reports, which used BAC
vectors as transgenes to establish transgenic mice (summarized in Tab.6.1).
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BAC PREPARATION prior to
INTRODUCTION into MURINE CELLS
BAC FORM
DNA PROCESSING AFTER
CLEAVAGE
REFERENCES
Microinjection
episomal - (Abe et al., 2004)
(Antoch et al., 1997)
linearized precipitated (Jessen et al., 1998)
(Mata et al., 2003)
(Yang et al., 1997)
(Antoch et al., 1997)
fragment isolated with gelase (Nielsen et al., 1997)
fragment isolated by electroelution (Chrast et al., 1999)
(Jiang et al., 2005)
(Al-Hasani et al., 2004)
linear fragment (*)
fragment isolated with agarase (Takahashi et al., 2000)
(Mullins et al., 1997)
(Vadolas et al., 2005)
(Chrast et al., 1999)
ES targeting
ES Electroporation
diluted with PBS (Heaney et al., 2004)
precipitated (Testa et al., 2003)
(Valenzuela et al., 2003)
linearized
extracted with phenol/chloroform (Yang and Seed, 2003)
ES Lipofection
episomal - (Ma et al., 2004)
Tab.6.1. Preparation of BAC-based transgenes for establishing transgenic mice. Both episomal
and linearized forms of BAC constructs were inserted into mouse genomes to give rise to transgenic
mice. BAC vector size ranges from 100 to 250kb. (*): BAC DNA was separated on PFGE and isolated
from the gel subsequently.
BAC constructs can encompass large mammalian gene loci or complete viral
genomes, such as EBV, but because of their large size they are more prone to
physical fragmentation than small plasmids (Giraldo and Montoliu, 2001). As a
consequence, they are more difficult to handle. More than fifteen years of extensive
research on BAC vectors, which were first introduced in 1989 (O'Connor et al., 1989),
have accumulated knowledge how to handle such large DNA molecules (reviewed in
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Giraldo and Montoliu, 2001). Publically available protocols describe BAC
manipulation in bacteria, DNA purification, linearization and preparation for
introduction into eukaryotic cells.
During my experiments two protocols were employed for BAC DNA purification from
bacteria: alkaline lysis followed by cesium chloride-ethidium bromide density (CsCl)
gradient centrifugation and Qiagen DNA isolation kits. Both techniques provided BAC
DNA of good quality, what was assessed by PFGE (Fig.5.15). Similar DNA
purification methods were employed in successful trials leading to BAC-transgenic
mice (Heaney et al., 2004; Jiang et al., 2005; Takahashi et al., 2000).
The maxi-EBV InvTarg targeting plasmid p3299.11 was introduced as a transgene
into murine cells in its linearized form upon digestion with PacI. Both unseparated
digested DNA fragments or individually prepared targeting fragments were
transduced into fertilized oocytes or ES cells. BAC DNA can be delivered into
mammalian cells in three different forms: episomal, linearized or as an isolated DNA
subfragment. All versions have been applied successfully while generating
transgenic mice (summarized in Tab.6.1). The episomal form is the easiest to handle
especially in its supercoiled form but linearization can assure transgene interruption
at the preferred site preventing accidental genetic instability of the recipient
chromosome (Giraldo and Montoliu, 2001). Moreover, linear fragments have been
observed to integrate more easily into mouse chromosomal DNA than intact plasmids
(Abe et al., 2004; Brinster et al., 1985). Separation of the targeting fragment from the
prokaryotic plasmid backbone is the most accurate and clean way of preparing the
transgene but also the most technically demanding approach (Giraldo and Montoliu,
2001).
Pulse Field Gel Electrophoresis (PFGE) was employed for the separation of the large
BAC DNA molecules. This method allowed estimation of the quality of the DNA
preparation after digestion and separation of the large targeting fragment from the
much smaller BAC plasmid backbone. In my work PFGE had an apparent advantage
as compared to standard horizontal electrophoresis (Fig.5.16a). The PFGE technique
was the basis for optimizing the cleavage conditions of BAC plasmid DNA. Although
PFGE cannot distinguish between intact DNA molecules and those with single strand
breaks, it can monitor overall DNA quality. On this basis, I could demonstrate the
range of cleavage conditions, which assured complete BAC DNA cleavage without
overdigestion (Tab.5.1).
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After the ‘simple cleavage’ with the restriction enzyme PacI, the InvTarg DNA was
purified prior to introduction into murine cells in order to minimize a potential harmful
influence on cell survival. The purification of the linear InvTarg vector was done with
a great care in order to avoid mechanical shearing of the DNA molecules. Four
different protocols were developed, which are described in chapter 5.4.4 of the
Results section: (i) enzyme inactivation (ii) followed by dialysis, (iii) DNA precipitation
and (iv) DNA fragment electroelution after PFGE.
Large BAC plasmids easily shear upon each physical manipulation, in particular as
linear DNA molecules. Therefore, treatment of the cleaved InvTarg construct was
limited to (i) heat-inactivation of the enzyme in ‘simply cleaved’ DNA preparation. The
subsequent dialysis (ii) was done to adjust the salt concentration of the DNA samples
prior to DNA injection or transfection. (iii) Precipitation of the transgenic DNA is a
standard method for a transgene preparation, and (iv) electroelution allows the
preparation of the targeting fragment and removal of other components of the
digestion mixture. Different sets of these purification protocols were chosen for each
procedure of DNA delivery into murine cells as described in detail in the Results
section (Tab.5.6 and 5.7).
The protocols chosen for the purification of cleaved BAC DNA reflect the procedures
adopted from successful projects leading to BAC-transgenic mice (summarized in
Tab.6.1). ‘Simple’ cleavage without subsequent enzyme inactivation, where the
digested preparation was either diluted with PBS (Heaney et al., 2004), or extracted
with phenol/chloroform (Yang and Seed, 2003), was successfully employed for BAC
transgenic mice derived from targeted ES cells. Exactly the same conditions for
enzyme inactivation are proposed by the Stanford School of Medicine
(http://med.stanford.edu/transgenic/dnamicro.html) for BAC DNA microinjection. DNA
dialysis was combined with electroelution (Chrast et al., 1999; Jiang et al., 2005) or
agarase treatment (Chrast et al., 1999; Mullins et al., 1997) of the PFGE separated
targeting fragment prior to microinjection. DNA precipitation (Jessen et al., 1998) and
electroelution (Al-Hasani et al., 2004; Chrast et al., 1999; Jiang et al., 2005) have
been already described as methods for BAC transgenic mice by microinjection.
Transgenic and Chimeric Facility from the University of Pennsylvania School of
Medicine also recommends BAC ethanol precipitation prior to microinjection
(www.med.upenn.edu/tcmf). The precipitation of large transgenes before their
transfection into ES cells is one of the preferred BAC processing methods employed
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(Testa et al., 2003; Valenzuela et al., 2003). In this study, the protocol for BAC DNA
precipitation (‘with FISHing’, chapter 4.3.14) was adopted from the collaborating
laboratory (THP, Bernried, Germany), which uses this method as a routine for
establishing BAC-transgenic animals.
6.2.2. Microinjection of InvTarg maxi-EBV targeting construct
The prepared linearized InvTarg targeting construct was microinjected into fertilized
murine oocytes in several attempts. The injected early embryos were transferred into
the foster mothers and gave rise to transgenic mice, which were analysed with PCR
for the presence of the randomly integrated InvTarg transgene.
Although the microinjection procedure was successful for all oocyte injections, it led
to transgenic litter in one case only. The other seven attempts led to early embryo
absorption in uteri and no offspring (Tab.5.7).
Parameters, which might have lowered the efficiency of establishing transgenic mice
by microinjection might include the quality of BAC targeting construct, its
concentration and the conditions of the injection.
The quality of each InvTarg DNA preparation was first approved with PFGE prior to
its injection. All the microinjected DNA samples are shown in Fig.5.26.
Any substance other than DNA or microinjection buffer could be lethal for the early
embryos (Vintersten et al., 2004). In my attempts with ‘simply’ PacI-cleaved vector
DNA without any further purification the inactivated enzyme could potentially be toxic
to the early embryos but one mouse was born alive after injection of the transgene,
which had been prepared in this way (Tab.5.7, No 5). In precipitated or eluted DNA
preparations the components of the restriction reaction had been removed.
Polyamines, such as spermidine and spermine, are components of the microinjection
buffer to stabilize the integrity of the transgene (Montoliu et al., 1995). Spermidine
and spermine are unstable during prolonged storage at non-optimal temperature
(Vintersten et al., 2004), but even if they had been degraded, there is no scientific
data demonstrating their toxicity to fertilized murine oocytes or mouse embryos.
Moreover, polyamines were found to be dispensable for the stability of BAC vector
DNA during oocyte microinjection (Giraldo and Montoliu, 2001). Considering the
careful and considerate DNA preparation in this work, there should be no toxic
ingredients contaminating the injected DNA solutions, but such a risk cannot be
completely excluded.
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The concentration of the microinjected InvTarg targeting construct did not exceed
2ng/ml, what is in line with publications dealing with establishing BAC transgenic mice
(Chrast et al., 1999; Nielsen et al., 1997; Takahashi et al., 2000). Higher
concentration increases the efficiency of transgene insertion but decreases the
viability of the embryos (Vintersten et al., 2004) and can result in multiple transgene
integrations. Based on the experience of our collaborators the DNA concentration
was even decreased to 0.25ng/ml. Thus, the concentration of the injected InvTarg
preparations was not too high in comparison to the references. In fact, the first
successful series used the InvTarg transgene concentration of 2ng/ml injection and
led to living offspring (Tab.5.7, No1). On the other hand, it is very unlikely that the
reduced BAC DNA concentration used in further attempts was responsible for no
offspring. If the transgene concentration was too low, non-transgenic wild-type mice
would have been born instead. Other groups, which had their BAC constructs
injected at the same facility, were successful with this low DNA concentration.
The microinjection procedure was conducted in the collaborating laboratory of E.Wolf
(Gene Centre, LMU, Munich) according to their standard protocol.
The analysis of born transgenic mice was based on PCR detection of selected loci
within the InvTarg maxi-EBV vector with four primer pairs as shown schematically in
Fig.5.24. Among six transgenic mice only one possibly had the entire InvTarg
construct integrated (Fig.5.27), but it was still-born. It is unclear whether its
decreased viability was due to insertional mutagenesis, which is a common event
upon random insertion (Williams and Wagner, 2000). This single event does not
support the general conclusion that integration of EBV genes could interfere with
mouse embryonic development. The other alive transgenic mice had only pieces of
the InvTarg targeting construct integrated. Namely, a fragment of viral ‘WW repeats’
was detected in all five mice (Fig.5.27). The ‘WW repeats’ region of the EBV genome
consists of up to 11 direct repeats (Bornkamm and Hammerschmidt, 2001). As a
consequence, it was impossible to determine the exact size of the integrated
fragment by PCR. The failure to detect the remaining parts of the maxi-EBV vector in
the chromosomal DNAs of the surviving mice was not due to insufficient sensitivity of
the PCR analysis. In reconstruction experiments I could unequivocally detect a single
copy of EBV DNA spiked into mouse cellular DNA samples (Fig.5.27, positive
control). Because the aim of my project was the chromosomal integration of the
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entire recombinant maxi-EBV targeting construct, the negative result with three out of
four primer pairs precluded further investigation of these transgenic animals.
In summary, several unidentified factors could have led to the failure to obtain a
transgenic EBV mouse upon microinjection. Many different preparations of the linear
InvTarg DNA were tested and the integrity of the large linear DNA molecules was
assessed with PFGE analysis, but single strand DNA breaks and DNA shearing
during transfer to the oocytes cannot be absolutely excluded. There was no hint to a
toxic compound contaminating the InvTarg DNA preparations and the concentration
of the injected samples rather did not constitute a problem either. Because one EBV-
transgenic mouse was still-born, EBV genes might have a detrimental effect on
mouse development.
6.2.3. Targeting of the linearized InvTarg maxi-EBV construct into the hprt
locus of Embryonic Stem (ES) cells
Murine Embryonic Stem (ES) cells were transfected with the linearized targeting
construct, InvTarg, and selected for its chromosomal integration. Targeted ES cells
were tested for the presence of the integrated transgene by PCR analysis.
The conditions for relative transduction of the InvTarg targeting construct into murine
ES cells were optimized in transient transfection experiments (Fig.5.22) but the
integration of the InvTarg vector into the ∆hprt locus of ES cells was observed only
once (Tab.5.6, ‘Reference’). The rest of the transfection trials are summarized in the
same table in relation to the single successful experiment.
Different parameters, which might have influenced the outcome, are discussed
below.
It has been shown by different groups that ∆hprt ES cell lines similar to the ones
used in my approach (HM1, E14) can give rise to transgenic mice with BAC DNA as
a transgene (Heaney et al., 2004; Testa et al., 2003). Moreover, the E14 cells were
successfully targeted with the linearized small control plasmid (Tab.5.3).
Among different ES cell targeting methods electroporation is the preferred one for
transfection of ES cells (projects summarized in Tab.6.1). In the initial transfection
attempts of my PhD work electroporation of the targeting construct was applied but in
the end it proved to be less efficient than lipofection (Tab.5.3). Murine ES cells were
shown to be effectively transfected by lipofection (Kobayashi et al., 2005; Wobus and
Boheler, 2005), also with lipofectamine2000 (L2000) (B.P. Murphy, personal
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communication). Unfortunately, no report exists on L2000-mediated transfection of
murine ES cells, particularly with BAC DNA. However, L2000 was used for efficient
transfections of different mammalian cell types (Ali et al., 2004; Dalby et al., 2004),
including delivery of BAC DNA (Kotzamanis et al., 2005; Magin-Lachmann et al.,
2004). Starting from the original Invitrogen protocol, lipofection with L2000 was
optimized with a small (20kb) plasmid (p3162) equipped with neomycin resistance
and hprt flanks (Tab.5.5). The main modifications addressed DNA concentration,
volume and cell culture medium used for incubation of the transfected cells with the
L2000-DNA complexes. The volume was reduced and a serum-free cell culture
medium was found superior. Further alterations of the protocol were necessary for
lipofections of the large maxi-EBV vector InvTarg DNA. The experiments were
transient transfections with maxi-EBV DNA carrying Green Fluorescent Protein (GFP)
and subsequent analysis of the number of GFP-expressing cells. The optimal
conditions found in these experiments were: 106 ES cells per well, 6mg BAC DNA
and 2.5ml L2000 per 1mg BAC DNA (Fig.5.23). These experimental settings are close
to the parameters used in similar approaches (Kotzamanis et al., 2005; Magin-
Lachmann et al., 2004). In these reports also serum-free media and reduced volume
were applied for incubation of the cells with transfecting agents.
A single approach was published, where BAC DNA was successfully integrated into
the hprt locus of ∆hprt ES cells in a site-specific manner, complementing a mutation
in murine hprt gene upon HAT selection (Heaney et al., 2004). A combination of both
G418 and HAT selection should allow identification of those ES cells that had the
entire InvTarg targeting construct integrated into the murine hprt locus, as the hprt
segment restoring the non-functional hprt gene and the neomycin resistance gene
neo were placed on both distal flanks of the targeting vector DNA molecule. The
selection mode optimized for the small control plasmid (p3162) comprised selection
with G418 for approximately one week followed by selection with a cell culture
medium with Hypoxanthine, Aminopterin and Thymidine (HAT) for another week
(‘neoÆHAT’; Tab.5.3). The average efficiency of the procedure reached 18 ES
colonies/106 cells. Under ‘HAT only’ selection the efficiency dropped to 2 colonies/106
cells, what was still comparable with related protocols [Heaney, 2004 #296; U.Strobl,
personal communication]. In addition, emergence of double (HAT and G418)
resistant cells proved that none of the compounds of selection medium was toxic to
the transfected cells. The most probable reason for the advantage of the ‘neoÆHAT’
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selection over the HAT medium alone was an improved initial survival of the
transfected cells under G418 selection in comparison to HAT. Successful
chromosomal integration of an intact BAC plasmid is a rare event compared with the
much smaller control plasmid p3162. The ES cells transfected with the InvTarg
construct were mainly selected with HAT selective medium alone, similar to the
published protocol (Heaney et al., 2004), because it selected for the specific
restoration of the murine hprt gene.
Targeting vector preparation, transfection and selection conditions varied slightly
between the many transfections into ES cells (Tab.5.6). The effects of these
alterations were examined in parallel to encounter hints for targeting ES cells more
efficiently. According to the one publication, the efficiency of BAC targeting into the
hprt locus in ES cells is one in 2-6x106 transfected ES cells (Heaney et al., 2004).
Because of the similarities between this published protocol and my attempts with
InvTarg targeting, the efficiency of the InvTarg plasmid integration was estimated to
be comparable. The different conditions were tested between 6 and 48 times, which
should result in the theoretical probability of at least two to around hundred
successful targeting events.
The single HAT-resistant ES cell clone was investigated for the presence of the
integrated InvTarg construct with PCR primers that amplify different parts of the
targeting (Fig.5.24). Three primer pairs (LOX71, I1 and LOX66) were designed to
detect a fragment placed in between and covering two loxP sites. The initial intention
was to verify the Cre-mediated re-inversion in transgenic ES cells. Unfortunately, the
single HAT-resistant ES clone had only fragments of EBV’s WW repeats integrated
(Fig.5.25). Again, as in the case of the microinjected InvTarg targeting vector
(chapter 6.2.2), it was impossible to determine the size of the integrated fragment
because the I1 primer pair did not discriminate between the eleven WW repeats
present in the InvTarg vector. The positive controls in the PCR reactions (Fig.5.25)
were also designed to simulate integration of a single copy EBV genome per cell. No
further attempt was made since this ES cell clone did not fulfil the expectations.
Because this ES cell clone survived in HAT medium, the partial insertion of the
InvTarg vector had restored the hprt locus but the neomycin resistance cassette was
non-functional or absent in this clone as the cells did not survive selection with G418.
In the conclusion, the developed targeting protocol of the small control plasmid
resulted in double resistant (against G418 and HAT) murine ES cells with a
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reasonable efficiency. The result of one positively targeted ES cell clone with
subgenomic fragments of the recombinant EBV vector integrated and a restored hprt
locus could be due to inadequate intactness of the transfected DNA molecules and/or
still insufficient transfection efficiency with the large InvTarg plasmid.
6.3. Outlook
DNA fragmentation might constitute a common problem for both approaches of
introducing BAC DNA into murine cells. Therefore, alternative approaches need to be
considered to overcome this problem.
6.3.1. Alternatives to the applied methods.
Optional transgene delivery and site-specific insertion
Covalently closed, circular forms of BAC vector DNAs are more stable than the linear
molecules of similar size (Vintersten et al., 2004). Thus, it would be technically much
less demanding if BAC episoms can be introduced into recipient cells and then
become integrated into the cellular genome. Site-specific recombinases (SSRs) are
able to stably insert circular vectors into a linear genome (reviewed in chapter 1.6.3,
and Fig.1.7). SSRs could be also used in this project. Because the Cre/loxP system
has been already employed as a switch in the InvTarg targeting vector, it cannot be
used here, but the Flp/FRT system is a realistic alternative as demonstrated already
(Dymecki, 1996). To improve the efficiency of the insertion, one could use mutated
FRT sites, which favour the unidirectional Flp-mediated integration (Branda and
Dymecki, 2004), similar to the lox71/lox66 sites used in my work. Optionally, fC31
integrase could be used for the site-specific vector insertion (Hollis et al., 2003).
Integrase-mediated recombination through the att sites also assures one-directional
reaction. Both Cre recombinase (Araki et al., 1995) and fC31 integrase (Hollis et al.,
2003) were reported to mediate recombination in the fertilized oocytes upon
microinjection of Cre-expressing plasmid or mRNA encoding integrase. Flp
recombinase was also employed for transgene recombination in fertilized oocytes
upon microinjection (Schaft et al., 2001).
Alternative ways of DNA delivery to ES
Nucleofection by Amaxa combines chemical transducers with a milder version of
electroporation and targets DNA molecules directly to the nucleus of transfected cell.
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This technique was used in delivering DNA to murine ES cells in both transient and
stable transfections (Kobayashi et al., 2005; Lakshmipathy et al., 2004). Besides,
Amaxa provides a kit with conditions adjusted to murine ES cells. Large BAC DNA
has been transduced with this technique to different cells, including human primary B
cells (C.Mancao, personal communication). This result indicates that the Amaxa
technology might be superior compared to chemical transfection procedure.
6.3.2. Inherent opportunities of the project
The construction of a Cre-regulated maxi-EBV vector is a novelty in the EBV field
and opens new opportunities for studying latent EBV genes in other cells but B
lymphocytes or during in vitro cell differentiation.
Transgenic mice harbouring the stably integrated EBV genome in all cells could be
manipulated by cross-breeding with different Cre-mice, to activate latent EBV gene
expression in different tissues or at distinct stages of organ development.
To my knowledge there is only one report in the literature, which succeeded in
introducing the entire viral genome - Human Immunodeficiency Virus (HIV) - into a
mouse gene locus (Hanna et al., 1998). Because this retroviral genome does not
exceed 10kb, the realisation of a transgenic EBV-mouse project would be a huge
step forward. Furthermore, it could become an example for the generation of animal
models with DNA viruses of similar sizes (100-200kb), like KSHV, which also lacks
many research options to study this virus thoroughly.
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7. SUMMARY
Epstein-Barr Virus (EBV) is involved in several human malignancies via its latent
gene products, which interact with cellular proteins and mimic discrete functions of
cellular signalling pathways. Enigmatically, more than 90% of the human population
carries this human tumour virus but virus-associated tumours are relatively rare.
Most studies on EBV have been carried out in vitro and ex vivo on EBV-transformed
human B cells or on human biopsies. Established in vivo model systems do not
reflect the main aspects of EBV-associated diseases in humans. This limited tool set
is the result of EBV’s inability to infect cells of non-human origin, which lack the
surface receptor for EBV.
My PhD work aimed at engineering a transgenic mouse, which carries a conditionally
inactivated EBV genome.
This study took advantage of the well-established techniques of mouse genetics in
order to stably integrate the entire EBV genome into the murine genome. This
approach would not only overcome the inability of EBV to infect animal cells but it
would also permit to study the complete virus in an immunocompetent and easy-to-
handle living organism.
I undertook two routes to establish a transgenic mouse with the complete EBV
genome inserted. One route was based on the site-specific integration into the hprt
locus of murine embryonic stem cells. The other route engaged pronucleus
microinjection of the EBV DNA into fertilized murine oocytes. In addition, the EBV
genome was genetically manipulated prior to its introduction into murine cells. On the
basis of the E.coli cloned EBV strain B95.8, I constructed a novel EBV mutant with
unique features. This EBV targeting construct (InvTarg) allows conditional expression
of EBV’s latent genes via a Cre/loxP system. Such approach prevents potentially
adverse effects of EBV’s latent genes on embryonic development but allows their
expression in almost any chosen cellular compartment for which specific Cre-
expressing mice are available.
The InvTarg recombinant EBV genome is 185 kb in size, based on a bacterial
replicon, and therefore belonging to Bacterial Artificial Chromosomes (BACs). Two
genetically modified and inversely oriented loxP sites were introduced in E.coli cells
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at the predetermined sites of the InvTarg, and the bracketed segment was inverted
by Cre recombinase, disrupting transcription of almost all viral latent genes. In
transgenic animals this inversion can be reverted and the latent genes can be re-
activated at will by cross-breeding with Cre-expressing mouse (re-inversion). The
ability of Cre to invert the big fragment was verified in infection experiments with
human primary B cells. As expected, the ‘inverted’ EBV construct, such as InvTarg,
failed to transform primary B cells, when the viral latent genes were not expressed.
Despite sustained efforts, both gene delivery techniques did not lead to a transgenic
mouse with the entire EBV genome inserted, but resulted in the integration of only
subgenomic segments of the InvTarg recombinant EBV DNA.
A number of technical problems were identified during this work, indicating more
specific direction for further research. On the basis of the experience gained here,
the project of an EBV transgenic mouse can be carried on. In addition, the InvTarg
maxi-EBV conditional vector might be employed in other experimental conditions, like
different cell types or distinct stages of cell differentiation, for studies on latent EBV
genes.
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Tab.1. Complete list of DNA constructs generated in order to generate the final
maxi-EBV targeting vector (InvTarg) with the necessary features. Part of these
plasmids were described in the thesis, only.
Bacterial Artificial Chromosome (BAC) constructs, originated in wild type maxi-EBV (p2089) are
marked with grey. Maxi-EBV plasmids contain entire genome of EBV and GFP. H.H.-Heidrun
Herrmann, W.H.-Wolfgang Hammerschmidt, D.P.-Dagmar Pich, M.Z.-Magdalena Zychlinska. Zeo-
zeocin, loxPinv-inverted loxP, tet–tetracycline, neo-neomycin. (*): ‘locked’ conformation, when loxP
sites are no longer substrates for Cre-recombinase, what stabilizes actual conformation created by
Cre.
Cloning
Step
Construct
Name
Features Made by
1.1 3060 pCR2.1 based; lox71site H.H.
1.2 3064 pSV40/Zeo2 based; loxP site H.H./M.Z.
1.3 3071 p288.1 based; floxed (with unidirectional lox71 and
loxP sites) zeo cassette set in context of LMP1
M.Z.
1.4 3080 p2089 based; floxed (with unidirectional lox71 and
loxP sites) zeo cassette in entire EBV genome context
M.Z.
1
1.5 3101 p3080 based; lox71 site M.Z.
2.1 3061 pCR2.1 based; loxPinv site H.H.
2.2 3068 pSV40/Zeo2 based; loxPinv site H.H./M.Z.
2.3 3072 p3068 based; floxed (with two loxPinv) zeo cassette M.Z.
2.4 3078 p3072 based; floxed (with two loxPinv) zeo cassette
set in context of Y 1, Y2 and EBNA2
M.Z.
2.5 3124 p3101 based; floxed (with two loxPinv) zeo cassette in
a ca.50kb distance to lox71
M.Z.
3125.3 p3124 based; region in between lox71 and loxPinv is
NOTinverted (EBV latent genes active)
M.Z.
2
2.6
3125.5 p3124 based; region in between lox71 and loxPinv is
inverted (EBV latent genes inactivated by inversion)
M.Z.
3.1 3108 p3078 based; inverted lox66 set in context of Y 1, Y2
and EBNA2
H.H.
3.2 3165 p3108 based; inverted lox66 set in context of Y 1, Y2
and EBNA2, and LMP1
H.H.
3.3 3213 pST76-amp based; shuttle plasmid (for chromosomal
buiding) with inverted lox66 set in context of Y 1, Y2
and EBNA2, and LMP1
H.H.
3
3.4 3221 p3125.5 based; region in between lox71 and inverted
lox66 is inverted (EBV latent genes inactivated by
inversion)
M.Z.
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3.5 3301 p3221 based; region in between lox71 and inverted
lox66 is re-inverted (EBV latent genes active; ‘locked’*
conformation)
M.Z.
4.1 3126 p995 based; disabled lytic origin of EBV, tet resistance
cassette (between two unidirectional FRT sites)
M.Z.
4.2 3274 p3221 based; region between lox71 and lox66
inverted, disabled EBV lytic origin, tet cassette
(between two unidirectional FRT sites)
M.Z.
4
4.3 3283 p3274 based; region between lox71 and lox66
inverted, disabled EBV lytic origin, single FRT site
M.Z.
5.1 2960 p2949 based; murine hprt flanks and human hprt
promoter, PacI site next to one hprt flank
D.P./W.H.
5.2 2996 p2960 based; murine hprt flanks and human hprt
promoter, PacI site next to one hprt flank, restriction
sites between both hprt flanks
W.H.
5.3 2997 p2996 based; murine hprt flanks and human hprt
promoter, restriction sites between both hprt flanks,
two PacI sites next to each of hprt flanks
W.H.
5.4 2998 p2997 based; murine hprt flanks and human hprt
promoter, restriction sites between both hprt flanks,
two PacI sites next to each of hprt flanks, a long flank
for recombination with maxi-EBV plasmid
W.H.
5.5 3033 p2998 based; murine hprt flanks and human hprt
promoter, restriction sites between both hprt flanks,
two PacI sites next to each of hprt flanks, both a long
and a short flank for recombination with maxi-EBV
plasmid
H.H./W.H..
5.6 3162 p3033 based; murine hprt flanks and human hprt
promoter, restriction sites between both hprt flanks,
two PacI sites next to each of hprt flanks, both a long
and a short flank for recombination with maxi-EBV
plasmid, PGK-neo cassette
H.H.
5.7 3260 p3162 based; murine hprt flanks and human hprt
promoter, restriction sites between both hprt flanks,
two PacI sites next to each of hprt flanks, both a long
and a short flank for recombination with maxi-EBV
plasmid, PGK-neo cassette, zeo resistance cassette
M.Z.
5.8 3164 pMBO131(MCS) based; combination of tet cassette
(between two unidirectional FRT sites) with F-factor
backbone (bacterial replicon for BACs)
M.Z.
5.9 3273 p3164 based; combination of tet and F-factor of p3164
with hprt and EBV flanks, neo and zeo of p3260
M.Z.
5
5.10 3299
(InvTarg)
p3283 based; final targeting construct with inverted
region between lox71 and lox66 (inactive EBV latent
genes), disabled EBV lytic origin, neo resistance and
hprt flanks, tet between two unidirectional FRT sites in
plasmid backbone and an additional single FRT site,
(no GPF)
M.Z.
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Tab.2. List of the ready plasmids used in the complete project of InvTarg vector
cloning procedure, and not mentioned in this thesis.
Plasmid name Features Source
pST76-amp Shu t t l e  p l asm id  f o r
chromosomal building
[Posfai, 1997 #402]
p2949 promoter and exon 1 of hprt
are of human origin, next two
hprt exons – of murine origin
[Bronson, 1996 #5c]
received from Ursula Strobl
(pMP9)
pMBO131(MCS) F-factor plasmid [O'Connor, 1989 #403]
